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Abstract 
 
Human endogenous retroviruses are remnants of ancient germline infections that 
make up approximately 8% of the modern human genome. Most HERVs entered 
primates approximately 40 million years ago, and have been rendered inactive due to 
the accumulation of mutations. However, one of the most recent entrants into the 
human germline is the HERV-K (HML-2) subfamily, most having only integrated 
between 200,000 and 5 million years ago. The HML-2 subfamily is the most conserved 
and transcriptionally active, and some members have retained functional open reading 
frames (ORFs) to code for all of their viral proteins. HERV elements exist in the human 
genome as retroviral genes (gag, pol, and env) flanked by two long terminal repeats 
(LTRs).  There are approximately 117 full-length copies and around 2500 solitary LTRs 
of HERV-K (HML-2) spanning multiple chromosomes. Even though no infectious HERV 
particle has been detected to date, HERV-K (HML-2) have been found to produce viral 
like particles in breast cancer, leukemia, lymphoma, melanoma, and teratocarcinoma. 
HERVs have been implicated in human biology, autoimmune diseases, and 
malignancies. There are two types of HERV-K (HML-2): type I is characterized by a 292 
bp deletion at the boundary of the pol and env genes, while type II contains the full 
sequence for pol and env. The deletion in the type I virus causes an alternative splicing 
event that results in the expression of the accessory protein Np9, while type II 
expressed the accessory protein Rec.  
 xv 
 
In our previous study, we have detected the activation of HERV-K type I 
proviruses in the blood of patients with HIV-1 infection. The HIV-1 infection activates the 
expression of a novel HERV-K (HML-2) provirus, which we termed K111, and it is 
present in multiple copies in the centromeres of chromosomes throughout the human 
genome. At the time of detection, the K111 virus was not annotated in the most recent 
human genome assembly. While a few copies of the K111 provirus appear in the 
genomes of the extinct Neanderthal and Denisovan, modern humans have a least 100 
copies of K111 spread across the centromeres of fifteen chromosomes, which suggests 
the expansion of K111 during the evolution of hominins. Most of the viral genes of K111 
are mutated and cannot produce viable viral products, with one exception: the K111 
virus contains an intact ORF for the Np9 protein and variants of Np9. For this reason, 
we investigated the effects of retaining the coding sequence for this accessory protein. 
 
To this end, we decided to study the role of HERV-K Np9 in teratocarcinoma 
cells. Teratocarcinoma cells have been shown to express HERV-K mRNA, proteins and 
produce viral like particles. Also, NCCIT teratocarcinoma cells have been shown to 
express K111 in their viral particles. We show that decreasing the expression of Np9 in 
NCCIT teratocarcinoma cells increases the sensitivity of NCCIT cells to chemical 
stresses (bleomycin and cisplatin) and environmental stress (serum starvation). Further, 
we determined that Np9 is essential to the migration of NCCIT teratocarcinoma cells. 
These findings support the implication that the HERV-K accessory protein Np9 has 
oncogenic potential.  
 1 
Chapter 1  
 
INTRODUCTION  
 
Part I. Discovery and identification of endogenous retroviruses 
 
Discovery of Murine Mammary Tumor Virus 
 
In 1933, a study published from the Jackson Memorial Laboratory suggested that 
the incidence of mammary tumors in laboratory mice was most likely a result of 
spontaneous development rather than the result of a genetic correlation. The study 
concluded that it is possible that the development of breast tumors have genetic and 
non-genetic influences, but that further experiments were necessary to determine the 
cause of breast cancer in laboratory mice (Jackson Memorial Laboratory 1933). 
 
In a later study published in 1936, researchers at the Jackson Memorial 
Laboratory investigated the possible effect of nursing on laboratory mice developing 
breast tumors. They noticed that a strain of their laboratory mice (inbred A strain) had 
an about 88% incidence of mammary gland tumors, while strain X (Strong’s CBA race) 
only had about a 10% incidence of developing mammary gland tumors. Combined with 
the previous study, investigators reasoned that laboratory mice perhaps developed 
 2 
breast tumors as a direct result of contracting a milk-borne pathogen through nursing or 
the physical act of nursing (Bittner 1936).  
 
 These investigators, led by John J. Bittner, thus wanted to determine if nursing 
from mothers with a high incidence of breast tumors had any influence on the offspring 
developing mammary tumors. For the study, the scientists took three litters of pups (at 
around or less than twenty-four hours old) from A stock mothers (high incidence of 
mammary tumors), and the pups were nursed by strain X foster mothers (low incidence 
of mammary tumors). There was a total of nine females in the foster litters. The fostered 
female pups reached adulthood, were bred, and nursed their subsequent progeny; the 
nine females produced a total of 40 pups. Therefore, the nine strain A female pups were 
foster nursed by strain X mothers, and had undergone all the necessary roles that were 
thought to be essential to the development of breast tumors. Three of the fostered 
females developed mammary tumors (33%), while four developed primary lung tumors 
(44%), and two never developed any tumors (23%). Further, investigators noted tumors 
in the subsequent progeny of the fostered female pups: twelve developed breast tumors 
(30%), two developed breast and pulmonary tumors (5%), thirteen developed primary 
lung tumors (33%), and thirteen never developed any tumors (33%). The study led 
researchers to believe that the incidence of mammary gland tumors was affected by 
nursing rather than a chromosomal influence (Bittner 1936). However, there were 
critical flaws in the experimental design and execution that rendered inconclusive 
results. For example, investigators separated the pups from their biological mothers at 
up to 24 hours old, meaning that these pups had already been nursed and might have 
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had contracted a milk-borne pathogen from their birth mothers; these pups should have 
been separated from their birth mothers at birth. Furthermore, if there was no genetic 
correlation to the incidence of mammary gland tumors, nursing the pups by the foster 
mothers should have resulted in the pups’ developing mammary gland tumors at the 
same percentage as the foster mothers. Also, if the physical act of nursing influenced 
the development of mammary gland tumors, the percentage of mice that developed 
mammary gland tumors would not fluctuate. The errors in experimental design are 
reasonable given how complex the etiology of mammary gland tumor is in laboratory 
mice.  
 
 A study published in 1942, led by Howard B. Andervont at the National Cancer 
Institute, found that milk is not essential for the development of mammary gland tumors, 
and the incidence of tumors is due to the milk-borne pathogen present in the milk of the 
mice with high incidence of mammary gland tumors. Also, investigators determined that 
the incidence of tumor development in mice depends on whether they were fed or 
subcutaneously injected with milk from mothers with a high incidence of mammary 
tumors, and the amount of milk administered (Andervont, Shimkin, and Bryan 1942). 
 
From the 1930s to 1960s, investigators performed many studies to identify the 
infectious milk-borne particle responsible for the high incidence of mammary tumors in 
laboratory mice (Nandi and McGrath 1973). The infectious milk-borne particle was given 
the name mouse mammary tumor virus (MMTV). A major breakthrough occurred in the 
late 1960s and early 1970s, when investigators identified MMTV as an endogenous 
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retrovirus (reviewed in Weiss et al. 2006). During that time, two other endogenous 
retroviruses were identified: the Avian Leukosis Virus (ALV), and the Murine Leukemia 
Virus (MLV) (Robin A. Weiss 2006). The discovery of these three endogenous 
retroviruses sparked the beginning of our understanding that the transmission of such 
viruses was not exclusive to infection (exogenous) but could also be transmitted 
genetically (endogenous), and that endogenous retrovirus had tumorigenic properties 
(Cohen, Majors, and Varmus 1979; Bentvelzen and Daams 1969; Bentvelzen et al. 
1970; Bentvelzen and Hilgers 1980).  
 
Retrovirus and endogenous retrovirus 
 
Retroviruses are infectious organisms belonging to the Retroviradae family, 
classified by their genetic material and life cycle. The Retroviradae family of viruses 
differ from other families in that most of these viruses contain genetic material 
consisting of Ribonucleic Acid (RNA), with the exception of Spumaviruses, which 
contain genetic material of consisting of Deoxyribonucleic Acid (DNA).  Interestingly this 
family of viruses have distinct biological features as part of their viral life cycle: 
1. The ability to convert their viral genetic material from RNA to DNA; 
2. The ability to insert their converted genetic material (RNA to DNA) into the host 
genome (Gifford and Tristem 2003; Gifford et al. 2005). 
These viruses received their name from the Latin retro, from their ability to defy 
the central dogma of molecular biology, in that genetic coding starts from DNA, with 
transcription into RNA, and then ultimately translation into proteins. However, in the 
 5 
case of retroviruses, which are generally RNA viruses, the viruses can reverse 
transcribe their RNA into DNA, then DNA is transcribed into RNA, and then finally 
translated into protein. As part of the retroviral life cycle (Figure 1.1), the virus must 
integrate the viral genetic material into the host, ultimately taking permanent residence 
within the host genome (reviewed in Balvay et al. 2007).  
 
A retroviral particle, also known as a virion, packages all components necessary 
to infect a host (Figure 1.2), complete the retroviral life cycle and propagate the next 
generation. On the surface of the virus is a lipid bilayer consisting of envelope proteins, 
a surface and a transmembrane glycoprotein. The inner layer of the virus contains three 
protein shells: the gag matrix protein surrounding the gag capsid protein, and the 
nucleocapsid (NC). The gag nucleocapsid protein encapsulates the viral genome (2 
single stranded RNA molecules), the reverse transcriptase (RT), and the viral integrase 
(IN) enzyme, each component playing an integral part in the life cycle of a RNA virus 
(Figure 1.3) (reviewed in Voisset, Weiss, and Griffiths 2008). In addition, complex 
retroviruses produce accessory proteins, for example the human immunodeficiency 
virus (HIV) expresses the Tat and Rev proteins, while the human endogenous 
retroviruses type-K (HERV-K) human mouse mammary tumor virus like-2 (HML-2) 
expresses the Np9 and Rec accessory proteins (discussed below) (reviewed in 
Cavallari et al. 2011).  
 
The Retroviradae family contains two subfamilies: Spumaretrovirinae and 
Orthoretrovirinae (Table 1.1). While Spumaretrovirinae has only one genus 
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(Spumavirus), Orthoretrovirinae contains six genera: alpha, beta, delta, epsilon, 
gamma, and lentiviruses. Alpha, beta, and gamma retroviruses have simple genomes, 
while delta, epsilon, and lentiviruses are retroviruses with complex genomes (see ICTV 
database https://ictvonline.org/index.asp). Most virus transmission comes about when 
an infected individual infects other individuals (horizontal transmission), such as it 
occurs with the Human Immunodeficiency Virus (HIV) and the Human T-cell Leukemia 
Virus (HTLV) (Coffin, Hughes, and Varmus 1997). The retrovirus and host dynamic can 
either be parasitic or symbiotic (Ryan 2004). Currently, we know that mammalian 
retroviruses can be parasitic in nature, but are also associated with tumors, 
immunodeficiency, autoimmunity and neurological disorders (Weiss 1996). For 
example, HIV is a retrovirus that is responsible for the depletion of CD4+ T cells in the 
host, ultimately resulting in the Acquired Immunodeficiency Syndrome (AIDS) (Okoye 
and Picker 2013).  
 
The endogenous retroviruses (ERVs) are a subset of retroviruses that share 
similar properties; however, they differ in one important aspect in that ERVs can and did 
infect a germ line cell (Nelson et al. 2003). Retroviruses are unique among the viruses 
because they can reverse transcribe their RNA genome and insert their genome into the 
host cellular DNA as part of the viral replication cycle (Gifford and Tristem 2003; Gifford 
et al. 2005). Normally, retroviruses are only capable of infecting somatic cells and, while 
the cell is proliferating, the virus can insert its retroviral genome into the host (Coffin, 
Hughes, and Varmus 1997). The inserted retroviral sequence exists in all progeny cells; 
this retroviral element inserted in the host genome is termed a provirus (Baltimore 
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1975). However, in the case of an endogenous retrovirus, they can effectively become 
“fixed” by infecting a germ cell and integrating their proviral elements into the host DNA. 
The offspring of an infected host would inherit the proviral element and any subsequent 
descendants would inherit the proviral elements in a Mendelian fashion (Gifford and 
Tristem 2003; Subramanian et al. 2011; Jern and Coffin 2008; Feschotte and Gilbert 
2012). Therefore, the mode of transmission of an endogenous retrovirus is considered 
“vertical”, meaning from parent to child (generation to generation), while the exogenous 
retroviruses are transmitted “horizontally”, from somatic cells to other somatic cells 
(within the same generation). Endogenous retroviruses have been found to be present 
in plants and vertebrates, from mice to humans (Bannert and Kurth 2006; Feschotte and 
Gilbert 2012; Herniou et al. 1998).  
 
Mouse Mammary Tumor Virus and the discovery of Human Endogenous 
Retroviruses  
 
Since its initial discovery, the mouse mammary tumor virus has been classified 
as a betaretrovirus, and is responsible for the incidence of mammary tumors in mice 
(see ICTV database https://ictvonline.org/index.asp). This virus exists as both an 
endogenous and exogenous virus, and replicates initially in lymphocytes (Nandi and 
McGrath 1973; Finke and Acha-Orbea 2001; Golovkina, Dudley, and Ross 1998). The 
infected lymphocytes carry the virus to the mammary gland, where they transmit the 
virus to the mammary epithelial cells (Golovkina, Dudley, and Ross 1998; Finke and 
Acha-Orbea 2001). The virus replicates within the mammary tissues, maximizing the 
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viral load within the mammary epithelial cells to maximize virion production, and 
ultimately inducing mammary tumors. The mammary tumorigenesis occurs after the 
proviral DNA integrates itself near host cellular proto-oncogenes, thus activating 
transcription (Callahan and Smith 2000). However, the MMTV integration is not site 
specific but, with more virion production, the likelihood that the proviral DNA will 
integrate near a proto-oncogene increases (Faschinger et al. 2008).  
 
The MMTV genome is approximately 9 kb, and the viral genome transcribes five 
different viral genes: gag, dut-pro, pol/in, rem and env (Ross 2008). The envelope (Env) 
protein is transcribed from the env gene, and functions in viral entry into host cells 
(Coffin, Hughes, and Varmus 1997). In addition, the Env protein is involved in MMTV-
mediated transformation, thus promoting tumorigenesis (Katz et al. 2005; Ross et al. 
2006). 
 
Shortly after the discovery of MMTV, researchers began looking for a human 
equivalent. At first, they detected MMTV-like proteins in human breast cancer biopsies 
by probing with antibodies against the mouse viral proteins (Mesa‐Tejada et al. 1982; 
Day et al. 1981), but that proved to be inconclusive. During the search for a MMTV-like 
sequence in human cellular DNA, Callahan et al. (1982) described finding a family of 
human endogenous retroviruses with sequence similarity to MMTV, one of the first 
descriptions of a human endogenous retrovirus in the human genome. Nonetheless, 
subsequent studies showed that there was no reactivity between human antibodies and 
MMTV proteins (Goedert, Rabkin, and Ross 2006). In 1986, Ono et. al cloned the full 
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sequence of the first human endogenous retroviruses related to MMTV, the provirus 
was termed HERV-K101 (Ono et al. 1986). Other investigators attempted to identify 
MMTV-like sequences in humans, and reported identifying MMTV-like sequences in 
30% of human breast cancers (Liu et al. 2001; Pogo et al. 1999), although a full MMTV-
like sequence has yet been identified. Investigators also reported finding MMTV-like env 
sequences by PCR in the DNA from human breast cancer tissue and, unlike MMTV, 
where env sequences can be found in normal mouse cells as well as mouse 
transformed mammary tissue, in humans the MMTV-like env sequences were tumor 
specific, and not detected in healthy tissue (Wang et al. 1995; Etkind et al. 2000). 
However, it is still unclear if a full MMTV sequence is present in human tumors or that 
the MMTV sequence in humans are the result of mouse contamination. Nonetheless, 
the use of MMTV probes led to the discovery of Human Endogenous Retroviruses 
(HERVs).  
 
Human Endogenous Retroviruses 
 
The commencement of the Human Genome Project resulted in the sequencing of 
3.2 billion base pairs in the human genome, giving us a vast amount of information 
about our DNA sequences. From this large collaborative project, we now know that only 
1.1% of our DNA sequence codes for protein, and the remaining 98.9% was considered 
“junk” DNA (Lander et al. 2001; Collins et al. 2004; Chial 2008). These sequences were 
referred to as “junk” DNA because at the time it seemed that they either had no 
biological function or their function was not yet known. However, it is becoming clear 
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that many of the these sequences are not “junk” after all and can serve as regulatory 
elements that are integral to the workings of cells, functioning as enhancers, promoters, 
silencers and insulators  (Maston, Evans, and Green 2006; Plank and Dean 2014). 
These “junk” DNA sequences also consists of repetitive elements, such as Alu 
elements, LINE and SINE elements (Long and Short Interspersed Nuclear Elements, 
respectively) and Human Endogenous Retroviruses (HERVs) (Subramanian et al. 2011; 
Weiss 2006; Bannert and Kurth 2006; Lander et al. 2001).   
 
One of the major insights from the Human Genome Project was that 8% of the 
human genome consisted of human endogenous retroviruses (Weiss 2006; Bannert 
and Kurth 2004; Subramanian et al. 2011). These exogenous retroviruses began to 
infect primates about 60 million years ago (about the same time that primates emerged) 
(Martin 1993), and subsequently these retroviruses became endogenized through 
integration of the viral genomes into the germ line. About 40 million years ago there was 
a divergence leading to the evolution of New World and Old World monkey lineages 
(Glazko and Nei 2003). Hominoidea (humans and great apes) emerged and separated 
from Old World monkeys about 35 million years ago. The last common ancestor of 
humans and chimpanzees lived about 6 million years ago (Martin 1993; Goodman 
1999). Since the initial infection and integration of retroviruses into the primate genome, 
new retroviruses have infected and integrated into the germ line, thus explaining the 
quantity of endogenous retroviruses in our genome today (Nelson et al. 2003; Jern and 
Coffin 2008; Subramanian et al. 2011).  
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It is estimated that there are more than 30 HERV families or lineages, however 
there are still HERVs that have not been classified due to fragmented or incomplete 
sequences (Gifford and Tristem 2003; Gifford et al. 2005). Since HERVs were once 
exogenous retroviruses, these viruses share the same genetic organization and 
structure, and are classified by their sequence similarities to other retroviruses. Human 
endogenous retroviral structure consists of the following: a 5’ LTR, PBS (primer binding 
site), gag, pro (protease), pol (polymerase), env (envelope), PPT (polypurine tract) and 
a 3’ LTR (Bannert and Kurth 2004). However, over the course of human evolution and 
subsequent re-infections and integrations, HERVs have accumulated insertions, 
mutations and deletions, rendering them as incomplete viruses (Hughes and Coffin 
2004). Therefore, the classification and grouping of HERVs is based on the pol 
sequence homology to other exogenous retroviruses, and each HERV family is denoted 
by a letter that signifies the resemblance to a specific primer binding site (Table 1.2) 
(Gifford and Tristem 2003; Cohen and Larsson 1988; Larsson, Kato, and Cohen 1989). 
For example, the primer binding site for HERV-K resembles that of the t-RNA binding 
site for lysine.  
 
Not all HERVs have been classified into retrovirus taxonomy due to their 
incomplete or fragmented sequences (Gifford and Tristem 2003; Gifford et al. 2005). 
Another major obstacle in finalizing a complete list of HERVs and their copy number is 
that the copy number within each group varies greatly and proviral sequences can also 
exist as solo LTRs. The advancement in bioinformatic tools has facilitated the detection 
and classification of retroviral elements in the genome. A recent study identified 3173 
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proviral sequences in the human genome, and upon further analysis of the HERV 
sequences they grouped 38% of them into specific groups (Class-I gamma-like or 
epsilon-like, Class-II beta-like, or Class-III spuma-like), whereas 62% of the HERVs 
remained unclassified (Vargiu et al. 2016). Even within each class there is 
heterogeneity in sequence, so most HERVs considered to be part of the same group 
almost never share exact homology.  
 
The discovery of endogenous retroviruses and their implication in diseases has 
sparked an interest in studying human endogenous retroviruses, especially as they 
make up a large quantity of our genome. To date, there is no known replication 
competent human endogenous retrovirus (Löwer et al. 1993; Seifarth et al. 1998; Bieda, 
Hoffmann, and Boller 2001), meaning there is no known HERV that maintained its 
ability to undergo all processes necessary to complete the viral life cycle and re-
integration. However, the more recently integrated families of HERVs have been shown 
to express some of their viral proteins (Tönjes et al. 1996; Seifarth et al. 1998; Johnston 
et al. 2001; Sugimoto et al. 2001; Wang-Johanning et al. 2001; Yi et al. 2001; Ruda et 
al. 2004). Since the initial infection of humans by exogenous retroviruses and their 
subsequent integration into germ line cells, these endogenous retroviruses have 
undergone mutations, deletions and insertions that have rendered them unable to 
replicate and form infectious viruses (Hughes and Coffin 2004). For some time, it was 
thought that these germ line infections were just remnants of ancient infections and did 
not have any biological purpose. However, in the 1970s it was discovered that some 
teratocarcinoma cell lines produce viral like particles (VLPs). The viral like particles 
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were later called human teratocarcinoma-derived viruses (HTDV) and it was later 
determined that a subfamily of Class-II HERVs were responsible for coding HTDV 
(Löwer et al. 1981; Löwer et al. 1993; Bieda, Hoffmann, and Boller 2001; Bhardwaj et al. 
2015). This later finding was a major milestone in the study of HERVs, as it was the first 
evidence that some family of HERVs were still capable of coding for their viral proteins 
and even produced particles, although they are perhaps incapable of replication. In the 
recent years, our laboratory demonstrated that VLPs produced by some 
teratocarcinoma and breast cancer cells lines can be passaged from cell to cell 
(Contreras-Galindo et al. 2015).  
 
HERV-K Human mouse mammary tumor-like group 2 (HML-2) (HK2) is a 
subfamily belonging to the Class-II beta-like group of HERVs (May and Westley 1986). 
To date, this subfamily of HERVs is known to be the most recent one to infect and 
integrate into the human genome with a few exceptions (Barbulescu et al. 1999; 
Okahara et al. 2004). Most of the HERV-K (HML-2) subfamily integrated itself between 
200,000 and 5 million years ago, it is the most conserved subfamily of retroviruses, is 
transcriptionally active, and has potentially functional open reading frames (ORFs) for 
all of its viral proteins (Tönjes et al. 1996; Seifarth et al. 1998; Johnston et al. 2001; 
Sugimoto et al. 2001; Wang-Johanning et al. 2001; Yi et al. 2001; Ruda et al. 2004). 
There are approximately 3000 HK2 sequences in the modern human genome (Paces et 
al. 2004). Of these, about 2500 exist as solo LTRs; however, about 117 HK2 full-length 
proviral sequences have been identified (Subramanian et al. 2011; Babaian and Mager 
2016; Wildschutte et al. 2016; Marchi et al. 2014; Contreras-Galindo et al. 2012; 
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Contreras-Galindo et al. 2013; Turner et al. 2001). It is the HERV-K (HML-2) subfamily 
upon which I focus on in this thesis.  
 
Part II. Human Endogenous Retroviruses and their implications in human disease 
 
HERV-K (HML-2) subfamily 
 
The class II HERV-K group family consists of subfamilies (HML-1 to HML-11), 
each a result of ancient germline infections (reviewed in Hohn, Hanke, and Bannert 
2013). The HERV-K (HML-2) subfamily is one of the most intensely studied subfamilies 
because, as one of the most recent entrants into the human genome (between 200,000 
to 5 million years ago), some of these viruses have undergone the least number of 
mutations, insertions and deletions. As a result, the HML-2 subfamily contains 
proviruses that have maintained complete or near complete open reading frames for all 
viral polyproteins. To date, there are 117 known HML-2 proviruses and more than 2500 
solitary LTRs in the genome (Subramanian et al. 2011; Babaian and Mager 2016; 
Wildschutte et al. 2016; Marchi et al. 2014; R. Contreras-Galindo et al. 2012; Contreras-
Galindo et al. 2013; Turner et al. 2001). Even though currently there are no known intact 
viruses capable of reinfection, there has been substantial evidence of HERV-K viral 
particles in certain cancers, and these viruses have maintained genome flexibility in that 
within the viral particles exists both potentially infectious RNA and DNA genomes exist 
(Seifarth et al. 1998; Büscher et al. 2005; Wang-Johanning et al. 2001; Bieda, 
Hoffmann, and Boller 2001; Löwer et al. 1993; Muster et al. 2003; Contreras-Galindo et 
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al. 2012; Contreras-Galindo et al. 2013; Contreras-Galindo et al. 2008; Contreras-
Galindo et al. 2007; Dube et al. 2014). 
 
There are two types of HERV-K HML-2 present in the genome, type I and type II, 
with the type I virus being characterized by the 292 bp deletion at the boundary of pol 
and env genes; type II does not contain such a deletion (N. Bannert and Kurth 2004). 
HERV-K have all the similar genes (gag, pro, pol, env) as other retroviruses, and much 
like complex retroviruses, it codes two accessory proteins: the type I virus encodes Np9, 
and type II encodes Rec (Figure 1.4) (Bannert and Kurth 2004).  
 
Complex retroviruses use intricate transcriptional regulation systems to control 
the expression of their viral mRNAs (Coffin, Hughes, and Varmus 1997). For instance, 
HIV produces primary transcripts that are unspliced to express the structural proteins 
Gag and Pol (Kim et al. 1989; Pomerantz et al. 1990). The viral Env glycoprotein is 
expressed from a singly spliced mRNA, while the accessory proteins Tat and Rev are 
expressed by mRNAs that are spliced multiple times. Complex retroviruses are not 
inherently efficient at splicing mRNAs, which results in nuclear retention or degradation 
of primary transcripts within the nucleus (Schneider et al. 1997; Maldarelli, Martin, and 
Strebel 1991; Nasioulas et al. 1994). However, the HIV Rev accessory protein functions 
as a regulatory protein and transports unspliced or partially spliced mRNA out of the 
nucleus and into the cytoplasm.   
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Interestingly, HERV-K also encodes an accessory protein to aid in the shuttling of 
unspliced or partially spliced mRNAs (Yang et al. 1999; Magin, Löwer, and Löwer 
1999). The HERV-K Rec accessory protein was first named as the central open reading 
frame (cORF), but later renamed to Rec due to its functional and sequence similarity to 
both HIV Rev and HTLV Rex (Lower et al. 1995). The Rev and Rex proteins are 
transported into the nucleus through the interaction of the nuclear localization signal and 
cellular import factors, and within the nucleus they function to suppress splicing, 
stabilize full length and singly spliced transcripts, and export transcripts to the cytoplasm 
(Magin, Löwer, and Löwer 1999). However, the expression of the other HERV-K 
accessory protein Np9 and its physiological importance or function is still not well 
understood, as is discussed below.  
 
HERVs and autoimmune disease and psychiatric disorders 
 
HERVs have long been implicated in multiple sclerosis and psychiatric disorders 
(Perron and Lang 2010; Antony et al. 2011; Slokar and Hasler 2016). Published work on 
HERVs describes an association with multiple sclerosis (MS), a chronic inflammatory 
demyelinating disease of the central nervous system (Trapp et al. 1998). The cause of 
the disease is highly debated and not well understood, but it is thought to be immune-
mediated, with association with genetic and possible viral factors. Several HERV 
transcripts and proteins have been detected in the central nervous system of patients 
with MS and patients with schizophrenia. Of the HERV families, HERV-W, HERV-H, 
HERV-F, and HERV-K have been reported to be associated with MS (Table 1.3) 
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(reviewed in Slokar and Hasler 2016). These HERV families exist as multiple copies in 
the genome, with some copies retaining coding potential for viral genes, some of which 
are activated in MS. Also, the multiple sclerosis retrovirus (MSRV), a member of the 
HERV-W family, has been reported in MS patients as a biomarker and a regulator of 
aberrant immune responses (Antony et al. 2011). Studies showed that serum and 
cerebral spinal fluid from patients with MS have detectable levels of MSRV in 50% of 
the French population and 100% of the Sardinian population, in 6% the blood of control 
groups, and 40% of patients with other neurological diseases (Garson et al. 1998; Serra 
et al. 2001; Dolei et al. 2002). Studies show that patients with MS with enhanced 
expression of MSRV in the brain and increased copy number in the blood have a poorer 
prognosis (Dolei et al. 2002; Serra et al. 2003). 
 
HERVs have also been associated with other autoimmune diseases such as 
systemic lupus erythematosus (SLE). Patients with SLE produce autoantibodies against 
components of the cell nucleus and double-stranded DNA; these autoantibodies can 
induce inflammation that can lead to arthritis, vasculitis, neurological disorders, and 
hypertension (Nakkuntod et al. 2013). Studies reported that T-cells from patients with 
active SLE contain global hypo-methylation and demethylation at promoters of many 
genes and contribute to the pathogenesis of the disease (Nakkuntod et al. 2013). Also, 
peripheral blood mononuclear cells (PBMCs) from SLE and rheumatoid arthritis patients 
show an elevated expression of HERV-E and HERV-K gag genes, respectively (Okada 
et al. 2002; Piotrowski, Duriagin, and Jagodzinski 2005; Ejtehadi et al. 2006). The 
implication is that hypo-methylation in SLE patients inadvertently activates the 
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expression of HERVs (Nakkuntod et al. 2013). Further, the rise of epigenetics has 
somewhat spurred a level of acceptance that the expression of certain HERVs is 
controlled or maintained by epigenetic mechanisms (Lavie et al. 2005).  
 
HERVs and skin diseases 
 
HERVs are also associated with skin diseases such as psoriasis, and viral like 
particles have been detected in skin lesional plaques, urine, and lymphocytes in 
individuals with psoriasis (Dalen et al. 1983; Iversen 1983; Guilhou, Vannereau, and 
Theunynck 1982). It is estimated that 2-3% of the world’s population is affected by 
psoriasis (Gupta et al. 2014). Psoriasis is an inflammatory skin disease in which 
keratinocytes proliferate in an uncontrolled manner and T-lymphocytes are recruited into 
the skin (Bessis et al. 2004). The expression of the mRNA of HERV-K, HERV-W and 
HERV-E has been shown to be elevated in lesional psoriatic skin when compared to 
non-lesional skin (Molès, Tesniere, and Guilhou 2005; Hohenadl et al. 1999), and 
HERV-E Env protein has been detected in psoriatic skin samples (Molès, Tesniere, and 
Guilhou 2005).  
 
HERVs and solid tumors 
 
HERVs have been implicated in solid tumors, and there is mounting evidence of 
HERV-K (HML-2) subfamily activation in germ cell tumors, ovarian cancer, melanoma, 
breast cancer, prostate cancer, lymphomas, leukemias, and sarcomas (Iramaneerat et 
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al. 2011; Wang-Johanning et al. 2007; Reiche, Pauli, and Ellerbrok 2010; Büscher et al. 
2005; Serafino et al. 2009; Ishida et al. 2008; Wang-Johanning et al. 2008; Golan et al. 
2008; Dehm 2008; Goering, Ribarska, and Schulz 2011; Contreras-Galindo et al. 2008; 
Depil et al. 2002; Schiavetti et al. 2002). Considering that 8% of the human genome 
consists of these ancient HERV infections, and the levels of viral mRNA, proteins and 
virions in various cancers, it is important to consider whether these ancient germline 
infections play roles in human malignancy (Table 1.4). The general understanding is 
that HERVs have the potential to cause disease or cancer through an array of 
mechanisms, such as the expression of oncogenes, the inactivation of tumor 
suppressor genes through mutational insertions, homologous recombination, and the 
transcription of oncogenes and growth factors through the LTRs (Gonzalez-Cao et al. 
2016). Many studies identified the expression of HERV proteins in cancer tissues, but 
the causative role of HERVs in cancer development remains controversial; however, 
data from animal models demonstrated that endogenous retroviruses are potentially 
oncogenic (Gonzalez-Cao et al. 2016). 
 
HERVs and placental development 
 
The expression of HERVs can also be beneficial for human development and 
expression of their genes has been detected in normal tissues. The mammalian 
placenta has elevated expression of endogenous retroviruses, and HERVs have been 
shown to play a critical role in placental development. The proper formation and 
expansion of the villous syncytiotrophoblast is crucial for the function of the human 
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placenta; the syncytiotrophoblast layer expands through intracellular fusion with the 
differentiating mononuclear villous cytotrophoblast. Certain HERV envelopes have been 
associated with placental development, including those from the families HERV-W and 
HERV-FRD, termed syncytin-1 and syncytin-2, respectively (reviewed in Bolze, 
Mommert, and Mallet 2017). These HERV envelope proteins are crucial for the 
evolution of the placental development and are thought to facilitate the retroviral 
transmission from mother to child. The syncytin proteins appear to be involved in 
maternal immune system suppression against the placenta, promote membrane fusion, 
and participate in the syncytiotrophoblast differentiation. Therefore, the retention of 
HERVs is essentially a double-edged sword, and their expression in human biology can 
either be beneficial or detrimental. 
 
Discovery of a previously unknown HERV-K (HML-2) type 1 virus termed K111  
 
In recent years, our research group identified a phylogenetically distinct HERV-K 
(HML-2) viral RNA sequences termed K111 in the blood of individuals afflicted with HIV-
1 but not in the blood of healthy individuals or patients with breast cancer or lymphoma 
(Figure 1.5A) (Contreras-Galindo et al. 2012; Contreras-Galindo et al. 2013). At the 
time, mining through the version of the annotated human genome we could not find the 
corresponding sequence. However, when we looked at the genome of one of our 
closest relatives, the chimpanzee, we located a virus similar to that of K111 in the 
telomere, close to the q arm of chromosome 7. These HERV-K sequences were only 
about 95% similar to those of the closest known HERV-K (HML-2) proviruses (HML-2), 
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but they were 98% similar to one provirus found in the genome of chimpanzee 
(Contreras-Galindo et al. 2013). Integration of HERV-K (HML-2) in human DNA 
produced 5-6 bp target site duplication sequences on each side of the provirus. The 
target site duplication is not apparent in all HERV-K (HML-2) proviruses, as homologous 
recombination between different HERV-K (HML-2) proviruses created hybrid proviruses 
with different flanking target site sequences (Hughes and Coffin 2005). Using this 
information, we designed primers that target the flanking regions and the internal viral 
genes of the K111 provirus to amplify K111 in humans by PCR (Figure 1.5B), and found 
that although K111 RNA was particularly expressed in the blood of patients with HIV 
(Figure 1.5A), K111 exists at the genomic DNA level in all the 189 human samples that 
we tested, including healthy subjects. K111 exists in the human genome as a full-length 
virus as well as a solo LTR. K111 integrated into the centromeric repeat CER:D22Z3, 
which has been assigned to the centromere of chromosome 22 (Dunham et al. 1999; 
Metzdorf, Göttert, and Blin 1988) and created a characteristic GAATTC target site 
duplication flanking each side of the proviruses after integration (Figure 1.5B).  
 
From our study, we discovered that during the course of evolution, the hundred 
to a thousand copies of K111 expanded by a mechanism similar to homologous 
recombination, and this virus is now detected in chromosomes 1, 4, 7, 9, 12, 13, 14, 15, 
17, 18, 20, 21, 22, X and Y, but not in the other human chromosomes; solo LTRs were 
detected in chromosomes 15 and 22 (Figure 1.6A and Figure 1.7). Furthermore, we 
determined that the integration of K111 took place around the time of the Homo-Pan 
divergence based on the molecular analysis of the LTRS of K111, and thus K111 
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insertions were only detected in chimpanzee and modern day humans, but not in other 
primates or monkeys (Figure 1.6B). Through the course of many recombination events, 
the K111 virus has accumulated mutations in the all of its viral genes with the exception 
of np9, suggesting that K111 is not capable of replication, but can still produce the viral 
Np9 accessory protein (discussed further in Chapter 2). Also, the NCCIT 
teratocarcinoma cell line has been shown to express the K111 provirus (Contreras-
Galindo et al. 2017). This further suggested that due to its abundance, Np9 might play 
an important role in human health and disease. Indeed, Np9 has been linked to 
oncogenesis, as we now will discuss.  
 
HERV-K accessory proteins and their interaction with PLZF and/or TZFP 
 
When Np9 or Rec is co-expressed with the promyelocytic zinc finger tumor 
suppressor protein (PLZF), which normally functions to repress the expression of the 
proto-oncogene c-myc, the interaction between Np9/PLZF or Rec/PLZF results in the 
sequestering of PLZF’s normal biological function, resulting in the de-repression of c-
myc. This de-repression promotes cell proliferation, which is particularly important 
considering that one of the hallmarks of cancer is unregulated cell proliferation (Denne 
et al. 2007). Much like PLZF, the testicular zinc finger protein (TZFP) acts as a 
transcriptional repressor of genes and, while the biological function of TZFP and the 
target genes is still not well understood, one of its functions is the interaction with and 
repression of the androgen receptor. A study showed that the interaction between 
HERV-K Rec and TZFP results in de-repression and transcriptional activation 
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(Kaufmann et al. 2010), and the inducible expression of Rec in the testis of transgenic 
mice resulted in the development of lesions similar to that of testicular germ cell tumors 
(Galli et al. 2005). Further, Rec supports germ cell tumor growth in mice through its 
interaction with PLZF. PLZF is a spermatogonia specific transcription factor that is 
essential for the regulation and maintenance of the sperm pool, and the improper 
control of spermatogenesis and maturation of gonocytes is thought to promote the 
development of germ cell tumors (Boese et al. 2000).  
 
Np9 interacts with the Numb protein in the Notch signaling pathway 
 
The Notch signaling pathway is highly conserved functions in developmental and 
homeostatic processes, and is known to be a pro-proliferative pathway; perturbations in 
the pathway can lead to oncogenesis (Aster, Pear, and Blacklow 2017). In simple terms, 
the canonical Notch pathway is activated through extracellular interactions between 
Notch ligands (Jagged-1, Jagged-2, Delta-like 1, 3 and 4) and Notch receptors (Notch 
1-4). The Notch receptors consist of an extracellular domain, a transmembrane portion, 
and an intracellular domain. Once activated, the Notch intracellular domain (NICD) 
undergoes a series of proteolytic cleavages by ADAM17, ADAM10, and γ-secretase, 
thus releasing the NICD and translocating to the nucleus. In the nucleus, the NICD 
interacts with the DNA-binding protein CBF1-Suppressor of Hairless-Lag1 (CSL) and 
the co-activator Mastermind-like-1 (MAML-1) to promote gene transcription. However, 
the notch pathway is inhibited by the Numb protein (Chillakuri et al. 2012). Mammalian 
Numb interacts with the RING-type E3 ubiquitin ligase and together tether the NICD 
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prior to its translocation to the nucleus, resulting in the proteasomal degradation of the 
NICD (Kopan and Ilagan 2009). Interestingly, the HERV-K Np9 accessory protein has 
been shown to interact with the RING-type E3 ubiquitin ligase LNX (ligand of Numb 
protein X), and alters the normal biological function of Numb, thus promoting the 
activation of the Notch signaling pathway (Armbruester et al. 2004). It is still unclear if 
the Np9, LNX and Numb interaction forms a trimeric complex, or if Np9 can sequester 
LNX from Numb.  
 
Np9 role in leukemogenesis  
 
A recent study investigated the role of HERV-K Np9 in the growth of leukemia, 
and the possible mechanisms of action. HERV-K Np9 was shown to be highly 
expressed in approximately 56% of leukemia patients, while it was hardly detected in 
CD34+ hematopoietic stem cells and healthy blood cells (Chen et al. 2013). The 
findings were that Np9 played a role in promoting the growth of leukemia cells, and 
immunocompromised NOD-SCID mice injected subcutaneously with Np9 over-
expressing Raji cells developed larger tumors than the control population. To further 
elucidate the function of Np9 in leukemia, the authors investigated the role of Np9 in 
different cell signaling pathways known to be abnormally activated in human leukemia, 
and Np9 activated the Wnt/ß-catenin, ras/ERK, and the c-myc/AKT signaling pathways, 
in addition to that of Notch1 (Chen et al. 2013). These findings have prompted us to 
search for a role for Np9 over-expression in another important malignancy that has 
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been particularly linked to over-expression of HERV-K virus and the production of viral 
particles, teratocarcinoma.  
 
 
 
THESIS FOCUS AND HYPOTHESIS 
 
In recent years, our group discovered a previously unknown HERV-K (HML-2) 
type 1 virus termed K111. We determined that there are hundreds to thousands of 
copies of the K111 provirus in the modern-day human genome, and the K111 provirus 
is present in many human chromosomes. Although this virus is highly mutated and is 
incapable of replication, it still contains the open reading frame for the viral accessory 
protein Np9. For this reason, we decided to study the function of the HERV-K accessory 
protein Np9 in teratocarcinoma cells. 
 
Teratocarcinoma is the ideal model for our studies, as teratocarcinoma cell lines 
over-express HERV-K virus and have been shown to produce viral like particles that 
contain K111 RNA. Treatment for teratocarcinoma has progressed since its discovery, 
with improved prognosis for patients, and since the introduction of platinum based 
therapy first year survival has greatly improved even with disseminated disease. 
However, it is estimated that 20% to 30% of patients with metastatic germ cell tumors 
relapse following initial treatments, and toxicity associated with the use of 
chemotherapeutic agents is still a major concern.  
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We hypothesized that the Np9 protein functions as an oncoprotein in 
teratocarcinoma, and could be targeted for therapeutics. We further found that the Np9 
accessory protein has oncogenic potential controlling viability and migration of 
teratocarcinoma, both of which are hallmarks of cancer. Our data presented in this 
thesis would suggest that targeting Np9 in teratocarcinoma will lead to better outcomes 
if proper drugs/delivery mechanisms can be obtained. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Simplified retroviral life cycle. Adapted from Voisset et al. 2008. 
 
 
Figure 1.2 Structure of a retrovirus particle. The 
virion is surrounded by a lipid bilayer derived from 
the host during the budding of a mature virus, and 
also contains the envelope glycoproteins (Env). 
Inside the lipid bilayer are three protein shells: the 
viral Gag matrix protein (MA) surrounding the Gag 
capsid protein (CA), and the nucleocapsid (NC). 
Encapsulated in the protein core is the viral 
genome (either as 2 copies of single-stranded 
RNA molecules or a double-stranded DNA 
molecule in the case of Spumaviruses, the viral 
reverse transcriptase (RT), viral protease (PR), 
viral integrase enzyme (IN), and cellular tRNA 
molecule. Adapted from Voisset et al. 2008.  
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Figure 1.3 The retroviral genome. Generalized retroviral genome in the RNA, DNA, and 
integrated forms. The conserved features of a retrovirus: repeated region (R), U3 and U5 unique 
elements, primer binding site (PBS) (used for initiation of reverse transcription), encapsidation signal 
(Ψ), polypurine tract (PPT). All infectious retroviruses have at least one splice donor (SD) and splice 
acceptor (SA) site used for the expression of a spliced transcript encoding env. During reverse 
transcription, the LTR is formed, which contains promoter and enhancer elements. At least four 
genes are present in all infectious retroviruses (gag, pro, pol and env). Additional retroviral proteins 
were described in Figure 1.2. Adapted from Voisset et al. 2008. 
 
 
 
Figure 1.4 Proviral organization of HERV-K (HML-2) and RNA transcripts. Adapted from Hohn et 
al. 2013. 
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A)  
 
 
 
 
 
 
 
 
 
 
 
B)  
 
 
 
 
 
Figure 1.5 Identification and genomic organization of K111 proviruses. (A) Quantitation of K111 
env titers by qRT-PCR in the plasma of patients with HIV-1 and other diseases. The K111 env titers 
were measured by qRT-PCR using the probe K111P that specifically discriminates the K111 env 
gene from other HERV-K (HML-2) env sequences due to a 6 bp mutation. K111 titers were detected 
in the plasma of patients with HIV infection but not in the plasma of healthy individuals or the plasma 
of patients with lymphoma or breast cancer. (B) Genomic organization of K111 full-length and Solo 
LTR, target site duplication “GAATTC”, and centromeric flanking sequences (CER:D22Z3). Frame 
shift (FS) and stop codon (asterisks) mutations are indicated. The positions of the primers used to 
amplify K111 5’LTR and 3’LTR insertions are indicated by arrows. Taken from Contreras-Galindo et 
al. 2013. 
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A)  
 
 
 
 
 
B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Expansion of K111 proviruses in humans took place after the Homo-Pan 
divergence. (A) Detection of K111 insertions in human chromosomes. DNA from human-hamster 
hybrid cell lines, which carry only one specific human chromosome, were analyzed by PCR for the 
presence of K111 using the set of primers that amplify the 5’LTR insertion as described. Other 
bands (for example the PCR products detected in chromosomes 3, 6, and 8) were shown by 
sequencing to be the result of non-specific PCR amplification. (B) Detection of K111 full-length and 
Solo LTR insertions from DNA of New and Old-World primates. Full-length K111 proviruses were 
detected by PCR only in the human and chimpanzee. The 5’ flanking K111 insertions were amplified 
with the primers P1/P7 and P4 and the 3’ flanking K111 insertions were amplified with the primers 
ET1 and P6. Solo LTRs were amplified by PCR using the primers P1 and P2 and were seen only in 
humans. Arrows indicate individual insertional polymorphisms. Taken from Contreras-Galindo et al. 
2013.  
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Figure 1.7 Identification of K111 
proviruses in individual human 
chromosomes. Bayesian inference tree 
of the 5’LTR and 3’LTRs, and flanking 
CER:D22Z3 sequences, of K111 
proviruses amplified from human 
chromosomes. Sequences are colored to 
indicate from which human chromosome 
they arise. Note that each color tends to 
cluster to specific evolutionary branches, 
indicating that individuals K111s often 
spread within an individual chromosome. 
Posterior probability values > 70 are 
shown for an unrooted tree. The tree was 
generated using Bayesian inference with 
four independent chains run for at least 
1,000,000 generations until sufficient trees 
were sampled to generate more than 99% 
credibility. 5’ (black), 3’ (blue) LTRs, and 
Solo LTR (red) lineages are shown along 
with the chimpanzee LTRs (CERV-K111). 
Informative nucleotide sequence 
substitutions were found that are specific 
for the K111 group of sequences found in 
each chromosome. Taken from Contreras-
Galindo et al. 2013. 
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Tables 
 
Table 1.1 Classification of the Retroviridae family. Adapted from Voisset et al. 2008 and the 
ICTV database https://ictvonline.org/index.asp. 
Subfamily and genus Species infected Example(s) 
Orthoretrovirinae   
     Alpharetrovirus Avian Avian Leukosis Virus  
Rous Sarcoma Virus 
     Betaretrovirus Mice  
Sheep 
Primates 
Mouse Mammary Tumor Virus 
 
     Gammaretrovirus Avian 
Cats 
Reptiles 
Primates 
Murine Leukemia Virus 
     Deltaretrovirus Cattle 
Primates 
Human T-lymphotropic virus 
     Epsilonretrovirus Fish Walleye dermal sarcoma virus 
     Lentivirus 
 
 
 
Primate 
Sheep 
Cats 
Horses 
Human immunodeficiency virus  
type-1 
Spumaretrovirinae   
     Spumavirus Primates 
Cats 
Cattle 
Human foamy virus 
 33 
HERV Family Primer Alternative Name 
Class I   
HERV-Z6969907 Not determined   
HERV-ADP tRNAThr ADP-pol 
HERV-E tRNAGlu  
HERV-F tRNAPhe  
HERV-F (type b) tRNAPhe  
HERV-FRD tRNAHis  
HERV-H tRNAHis RTLV-H 
HERV-H49C23 No LTRs  
HERV-I tRNAIle RTLV-I 
RRHERV-I tRNAIle  
ERV-9 tRNAArg  
HERV-F (type c) tRNAPhe  
HERV-P tRNAPro HuRRS-P 
HERV-R tRNAArg  ERV-R 
HERV-R (type b) tRNAArg  
HERV-T tRNAThr HERV-S71 
HERV-W tRNATrp MSRV 
HERV-XA tRNAPhe  
Class II   
HERV-K (HML-1 to HEML-4) tRNALys  
HERV-K (HML-5) tRNAIle  
HERV-K (HML-6) tRNALys  
HERV-K (HML-9) Not determined   
Class III   
HERV-L tRNALeu  
HERV-S tRNASer  
HERV-U2 Not determined  
HERV-U3 Not determined  
 
Table 1.2 Classification of HERVs. Adapted from Gifford and Tristem 2003. 
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HERV Disease associations Specific action 
HERV-F/H Multiple sclerosis in 
addition to certain cancers 
Expressed in MS patients, particularly in 
lymphocytes 
HERV-W Multiple sclerosis and 
schizophrenia 
Expressed in white matter lesions in MS 
patients, association with schizophrenia 
also reported 
HERV-K Multiple sclerosis Disease marker 
Table 1.3 HERVs and associations in MS and schizophrenia. Taken from Anthony et al. 2011.  
 
 
 
Tumor type HERV transcripts HERV proteins 
Ovarian env, np9, rec Env 
Melanoma pol, env, gag, env, rec Pol, Env, Gag, Rec, Np9 
Prostate gag, env, np9 Gag 
Lymphoma gag, env Env 
Leukemia (CLL, CML, ALL) pol,  Env 
Germ cell seminoma gag, env, np9, rec Gag, Env, Np9, Rec 
Breast env, gag, rec Env, Rec 
 
Table 1.4 HERV-K (HML-2) activation in solid tumors. In addition, HERV-K viral particles are 
expressed in all tumor types listed in the table with the exception of ovarian cancer (Wang-
Johanning et al. 2007, 2013, 2008; Zhao et al. 2011; Wang-Johanning et al. 2012; Golan et al. 2008; 
Herbst, Sauter, and Mueller-Lantzscht 1996) 
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Chapter 2  
 
THE HERV-K ACCESSORY PROTEIN NP9 CONTROLS VIABILITY AND 
MIGRATION OF TERATOCARCIONOMA CELLS 
 
 
The work presented in this chapter was submitted to the online journal PLOS One and is 
currently under revision. All experiments were performed by Susana M. Chan. 
 
 
Abstract 
 
Human endogenous retroviruses are remnants of ancient germline infections that 
make up approximately 8% of the modern human genome. The HERV-K (HML-2) family 
is one of the most recent entrants into the human germline, these viruses appear to be 
transcriptionally active, and HERV-K viral like particles (VLPs) are found in cell lines 
from a number of human malignancies. HERV-K VLPs were first found to be produced 
in teratocarcinoma cell lines, and since then teratocarcinoma has been thought of as the 
classical model for HERV-Ks, with the NCCIT teratocarcinoma cell line particularly 
known to produce VLPs. Treatment for teratocarcinoma has progressed since its 
discovery, with improved prognosis for patients. Since the introduction of platinum 
based therapy, first year survival has greatly improved even with disseminated disease; 
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however, it is estimated that 20% to 30% of patients present with metastatic germ cell 
tumor relapse following initial treatments. Also, the toxicity associated with the use of 
chemotherapeutic agents used to treat germ cell tumors is still a major concern. In this 
study, we show that the depletion of the HERV-K accessory protein Np9 increases the 
sensitivity of NCCIT teratocarcinoma cells to bleomycin and cisplatin. While decreasing 
the expression of Np9 had only a modest effect on the baseline viability of the cells, the 
reduced expression of Np9 increased the sensitivity of the teratocarcinoma cells to 
environmental (serum starvation) and chemical (chemotherapeutic) stresses. Np9 is 
also essential to the migration of NCCIT teratocarcinoma cells: in a wound closure 
assay, reduced expression of Np9 resulted in cells migrating into the wound at a slower 
rate, whereas reintroduction of Np9 resulted in NCCIT cells migrating back into the 
wound in a manner similar to the control. These findings support the implication that the 
HERV-K accessory protein Np9 has oncogenic potential.  
 
Introduction 
 
Human endogenous retroviruses (HERVs) account for 8% of the human genome, 
yet their potential roles in the biology of the cell and in human health or disease remain 
poorly understood. These ancient viruses were once exogenous viruses that infected 
germ cells of mammals and other vertebrates numerous times in the course of millions 
of years, and subsequently integrated their proviral elements into the host genome. 
These proviruses have then been transmitted over the generations in a Mendelian 
fashion (Subramanian et al. 2011; Nelson et al. 2003; Jern and Coffin 2008). HERV 
elements exist in the human genome as retroviral genes (gag, pol, and env) flanked by 
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two long terminal repeats (LTRs); the LTRs serve as transcriptional promoters (Bannert 
and Kurth 2004). However, most of the HERV proviral sequences have been rendered 
nonfunctional due to the accumulation of mutations, insertions, and deletions in crucial 
retroviral genes (Hughes and Coffin 2004), with the possible exception of the HERV-K 
(HML-2) subfamily. The HERV-K (HML-2) subfamily is one of the most recent entrants 
into the human genome, most having only integrated itself between 200,000 and 5 
million years ago, and it is the subfamily of endogenous retroviruses that is most 
conserved and are transcriptionally active, and some have functional open reading 
frames (ORFs) to code for all of its viral proteins (Barbulescu et al. 1999; Okahara et al. 
2004; Tönjes et al. 1996; Sugimoto et al. 2001; Bannert and Kurth 2004; Wang-
Johanning et al. 2001).  
 
There are approximately 117 full-length copies and more than 2500 solitary LTRs 
of HERV-K (HML-2) spanning multiple chromosomes (Subramanian et al. 2011; 
Babaian and Mager 2016; Wildschutte et al. 2016; Marchi et al. 2014; Contreras-
Galindo et al. 2012; Contreras-Galindo et al. 2013; Turner et al. 2001). In addition, our 
group has discovered that there are at least hundreds of copies of the HERV-K (HML-2) 
virus found throughout the centromeres of multiple chromosomes, a type-I provirus that 
we have termed K111 (Contreras-Galindo et al. 2013; Zahn et al. 2015). There are two 
types of HERV-K (HML-2) viruses: type I is characterized by a 292-bp deletion at the 
boundary of the pol and env genes, while type II contains the full sequence for pol and 
env.  In the type I virus, the 292-bp deletion causes an alternative splicing event that 
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results in the expression of the accessory protein Np9, while type II expresses the 
accessory protein Rec (Bannert and Kurth 2004).  
 
The transcription and translation of HERV-K genes and proteins are thought to 
be tightly repressed under normal physiological conditions, but there is evidence of 
HERV-K reactivation in different malignancies. For example, even though no infectious 
HERV particles have been detected to date, HERV-K (HML-2) have been found to 
produce viral like particles (VLP) in the tumor tissues of patients with breast cancer, 
leukemia, lymphoma, melanoma, and teratocarcinoma, and in the blood of HIV-infected 
individuals (Seifarth et al. 1998; Wang-Johanning et al. 2001; Bieda, Hoffmann, and 
Boller 2001; Büscher et al. 2005; Löwer et al. 1993; Muster et al. 2003; Contreras-
Galindo et al. 2012; Contreras-Galindo et al. 2013, 2006; Contreras-Galindo et al. 2008; 
Contreras-Galindo, Almodóvar-Camacho, et al. 2007; Contreras-Galindo, López, et al. 
2007). In addition, the increased transcription and expression of the HERV-K accessory 
proteins Np9 and Rec are thought to have potentially important roles in cellular 
functions that may contribute to oncogenesis (Kaufmann et al. 2010; Denne et al. 2007; 
Galli et al. 2005; Chen et al. 2013; Armbruester et al. 2004). 
 
HERV-K Rec is a 14 kDa protein that is a functional homolog of HIV Rev (Yang 
et al. 1999; Magin, Löwer, and Löwer 1999). Rec aids in the shuttling of unspliced 
mRNA out of the nucleus, and has been associated with tumor development similar to 
testicular carcinoma in nude mice (Galli et al. 2005; Yang et al. 1999). The HERV-K 
accessory protein Np9 is a 9 kDa protein that shares its first 14 amino acids with HERV-
 39 
K Rec, both of which are translated from the HERV-K env reading frame (Armbruester 
et al. 2002). A recent study showed that the np9 and rec transcripts are not restricted to 
disease states (Schmitt et al. 2015). However, the actual HERV-K Rec and Np9 
accessory proteins appear to be expressed mainly in malignant tissues. Rec and Np9 
proteins have been detected in primary and metastatic melanoma biopsies and 
melanoma cell lines but not found in melanocytes (Muster et al. 2003; Büscher et al. 
2006). Also, np9 transcripts have been found in transformed cell lines and tumors such 
as mammary carcinomas, germ cell tumors, and leukemia blood lymphocytes 
(Armbruester et al. 2002).  
 
The role that these accessory proteins play in promoting oncogenesis is still not 
well defined. However, there has been some progress in identifying potential interacting 
partners and the functions of these accessory proteins in different cellular pathways. 
HERV-K Np9 and Rec have both been shown to physically and functionally interact with 
the promyelocytic zinc finger (PLZF) tumor suppressor and inhibit its function as a 
transcriptional repressor. The PLZF tumor suppressor is a known transcriptional 
repressor of the c-myc proto-oncogene. The co-expression of Np9 or Rec with PLZF 
removes the transcriptional repression of the c-myc promoter by PLZF, resulting in the 
overexpression of c-Myc and altered expression of c-Myc regulated genes, thus 
affecting cell proliferation and survival (Denne et al. 2007). HERV-K Np9 has also been 
shown to interact with the RING-type E3 ubiquitin ligase LNX (ligand of Numb protein X) 
(Armbruester et al. 2004), and Np9 has been found to play a critical role in different cell 
signaling pathways by activating β-catenin, ERK, Akt and Notch1 (Chen et al. 2013). 
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The expression of Np9 is crucial for the survival and growth of myeloid and 
lymphoblastic leukemia cells: reduced expression of Np9 caused growth inhibition of 
myeloid and lymphoblastic leukemia cells, whereas overexpression of Np9 promoted 
the growth of leukemia cells (Chen et al. 2013). Lastly, NOD-SCID mice developed 
larger tumors at a faster rate when injected subcutaneously with lymphoma cells 
overexpressing Np9 as compared to mice that received lymphoma cells with a control 
vector  (Chen et al. 2013). Further studies are necessary to examine the role of Np9 in 
other types of tumors.  
 
In the studies presented here, we investigated the function of Np9 in 
teratocarcinoma, a classical model for HERV-K and cancer. It was in teratocarcinoma 
cell lines that investigators first saw the production of VLPs, first termed human 
teratocarcinoma-derived viruses (HTDV), and it was later determined that HERV-K was 
responsible for encoding HTDV (Bhardwaj et al. 2015; Löwer et al. 1981; Bieda, 
Hoffmann, and Boller 2001; Boller et al. 1993). HERV-K (HML-2) mRNA and proteins 
are also highly expressed in teratocarcinoma (Götzinger et al. 1996; Armbruester et al. 
2002). Also, the NCCIT teratocarcinoma cell line has been shown to express K111 
(Zahn et al. 2015; Contreras-Galindo et al. 2017).The aim of the present study was to 
investigate whether the expression of Np9 supports or promotes tumorigenesis. We 
show that decreasing expression of Np9 with CRISPR/Cas9 decreases the viability of 
the NCCIT teratocarcinoma cell line when it is subjected to environmental  stress 
(serum starvation) or chemotherapeutic agents (bleomycin and cisplatin) that are used 
in clinical settings as a part of a cocktail to treat testicular germ cell tumors (TGCT) 
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(Price and Peters 1992; Meyts et al. 2015; Dasari and Bernard Tchounwou 2014; 
Malavalli, Karra, and Muniyappa 2013; Williams et al. 1987; Winter and Albers 2011). 
Further, the reduced expression of Np9 decreased cell migration and invasiveness of 
teratocarcinoma cells, and re-introduction of Np9 rescued the migration of the NCCIT 
teratocarcinoma cells. Thus, we show that Np9 is crucial to the viability and mobility of 
teratocarcinoma cells, and decreasing its expression can potentiate the effectiveness of 
chemotherapeutic agents used in the clinic.  
 
Results 
 
Np9 controls cellular viability when teratocarcinoma cells are stressed 
 
In view of the potential link between Np9 and teratocarcinoma, we performed 
loss-of-function studies to investigate the role of Np9 in the viability of the NCCIT 
teratocarcinoma cell line.  We used two independent CRISPR/Cas9 constructs to make 
permanent cell lines in which Np9 expression had been knocked down. The 
CRISPR/Cas9 system is an efficient gene editing system that uses guide RNAs 
specifically designed to target and edit the gene of interest (Wang, La Russa, and Qi 
2016); in our study, we used two independent Np9 guide RNAs to knock-down and 
reduce the number of Np9 copies in NCCIT teratocarcinoma cells, and isolated 
individual clones. Typically, the CRISPR/Cas9 system is used to mutate or knock-out 
(KO) a gene of interest (Lieber 2010; Wang, La Russa, and Qi 2016). Given the high 
number of Np9 gene copies in the human genome and the sequence heterogeneity 
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from one Np9 locus to another, the use of CRISPR/Cas9 is expected to result in a 
partial knock-down (KD). For example, the type I virus K111 discovered by our group 
can be found in hundreds of copies across 15 different centromeres (Contreras-Galindo 
et al. 2012; Zahn et al. 2015; Contreras-Galindo et al. 2013). Although the K111 
proviruses do not seem to be replication competent, they code for many Np9 proteins, 
including some variants.  
 
In our study, we used two independent Np9 guide RNAs to knock-down and 
reduce the number of Np9 copies in NCCIT teratocarcinoma cells. As can be seen in 
Figure 2.1A, knocking down the expression of Np9 was successful. However, the 
reduced expression of Np9 varied among the different clones that were isolated. In the 
two knock-down clones presented in this study, the expression of Np9 was reduced 
approximately by 80% and 20% in the knock-down clones 8 and 9, respectively. Np9 
protein expression can only be seen after treatment with epoxomicin to inhibit the 
proteasome pathway, as Np9 typically has a very short half-life (Armbruester et al. 
2004).  Even though Np9 is a 9 kDa protein, it has been shown to be represented as a 
12.5 kDa signal (Heyne et al. 2015), perhaps due to post-translational modifications. 
When Np9 was knocked down, we observed that it had a modest effect on the growth of 
NCCIT cells as represented by the MTT assay, which measures metabolic activity 
(Figure 2.1B).  When we further examined the effect of Np9 knockdown in this 
teratocarcinoma cell line, consistent with the modest impact on cell viability we found 
only a small alteration in the cell cycle distribution, more so in Np9 KD clone 8 that 
causes a greater reduction in Np9 expression (Figure 2.1C).  However, many 
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oncoproteins, as well as other biologically crucial molecules, exert their effects primarily 
under duress.  Therefore, we subjected the knock-down and control cells to serum 
starvation, and found a marked reduction in cellular metabolism in the two knock-down 
clones (KD clone 8 and clone 9) as compared to a clone in which only a scramble 
CRISPR/Cas9 guide RNA was used (Figure 2.1D).  Therefore, taken together, we see 
that the reduction in the levels of Np9 does have a significant effect on the growth and 
metabolism of this type of cancer cell, but primarily when the cells are put under stress.  
This prompted us to move on to examine the effect of Np9 knock-down in the setting of 
chemotherapeutic agents used in the clinic.   
 
Decreased Np9 expression increases sensitivity of teratocarcinoma cells to 
chemotherapeutic agents 
 
In the clinical setting, testicular teratocarcinomas are frequently treated with 
combinations that include bleomycin and cisplatin, two highly toxic agents (Williams et 
al. 1987; Winter and Albers 2011; Dasari and Bernard Tchounwou 2014; Price and 
Peters 1992; Meyts et al. 2015).  As decreasing Np9 expression sensitized NCCIT cells 
to starvation stress, we next investigated whether cells that had Np9 expression 
knocked down would be more susceptible to chemical stress induced by bleomycin and 
cisplatin. Indeed, when Np9 expression was diminished NCCIT cells treated with 
bleomycin (Figure 2.2A) or cisplatin (Figure 2.2B) for 48 hours showed markedly 
reduced cell viability. This loss of viability was seen with both Np9 KD clones, as 
compared to the scramble control.  
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By appearance, the NCCIT cells in which Np9 was knocked-down appeared to 
be apoptotic through the loss of adhesion.  We therefore stained NCCIT cells (KDs and 
Scr control) with activated Caspase 3/7 green detection dye and SYTOX AADvanced 
viability dye to discriminate early and late stage apoptotic cells from live and dead cells. 
We found that, in spite of the limited effect on overall growth and metabolism as 
measured by MTT assay (Figure 2.1B), diminished Np9 expression did lead to some 
increase in apoptosis even in the absence of any stress (Figure 2.3).  However, this 
increase in apoptosis was magnified when bleomycin was applied to the cells (Figure 
2.3).   
 
Decreasing Np9 levels severely affects migration of NCCIT cells 
 
The data above demonstrate that the effect of Np9 on the growth, metabolism, 
and viability of teratocarcinoma cells is particularly visible when the cells are put under 
stress. We therefore wanted to examine another aspect of oncogenesis that reflects cell 
migration, and so employed a wound-closure assay.  In this assay, a scratch is induced 
to cells growing in a monolayer and then the time it takes for the “wound” to close is 
monitored.  This is one important test for examining the contribution of a cellular protein 
to the oncogenic process (Sahai 2005; Hulkower and Herber 2011).  As can be seen in 
images in Figure 2.4A and graphically in Figure 2.4B, knocking down Np9 expression 
with CRISPR/Cas9 led to a marked slowing in wound closure.  At 24 hours (Figure 
2.4B), the wound closure was only approximately 25% to 50%, as opposed to 
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somewhere between 75% and 90% in the control cells.  Therefore, a decrease in Np9 
expression clearly affects the ability of cells to migrate.   
 
In order to confirm that Np9 is crucial to wound healing, we employed the 
piggybac system to stably overexpress the Np9-mCherry fusion protein; the mCherry 
was used as a visual indicator for the stable expression of Np9. Strikingly, when we 
overexpress Np9 in the NCCIT cells in which Np9 expression has been reduced with 
CRISPR/Cas9 editing, the wound healing is restored essentially to normal.  This is seen 
in the pictures in Figure 2.5A and is depicted graphically in Figure 2.5B, showing that 
we were able to restore migratory function of the teratocarcinoma cells by reintroducing 
Np9. This rescue experiment offers striking evidence that Np9 is important to wound 
closure in NCCIT cells, and further suggests an important role for this protein in the 
growth and movement that is necessary for oncogenesis. 
 
Discussion 
 
HERVs have long been implicated in autoimmune disorders and oncogenesis 
(Balada, Ordi-Ros, and Vilardell-Tarrés 2009; Urnovitz and Murphy 1996; Perron and 
Lang 2010; Curtin et al. 2012; Mameli et al. 2012; Iramaneerat et al. 2011; Wang-
Johanning et al. 2007; Reiche, Pauli, and Ellerbrok 2010; Büscher et al. 2005, 2006; 
Serafino et al. 2009; Wang-Johanning et al. 2001, 2003, 2008; Goering, Ribarska, and 
Schulz 2011; Ishida et al. 2008; Contreras-Galindo et al. 2008; Depil et al. 2002; 
Schiavetti et al. 2002).  However, the fact that there are so many copies, over a hundred 
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copies of the standard HERVs and hundreds to thousands of copies of K111 and K222, 
picking apart the specific contributions of HERV-K to cancer has been quite difficult 
(Contreras-Galindo et al. 2013; Zahn et al. 2015).  Adding to the complexity of HERV-K 
biology in the context of human diseases, there is evidence of HERV-K viral particle 
production in certain cancers and transformed cell lines, such as teratocarcinoma; 
however, whether these viral particles are actually replicative remains unknown and the 
subject of debate (Contreras-Galindo et al. 2012; Turner et al. 2001; Löwer et al. 1993; 
Seifarth et al. 1998; Muster et al. 2003; Büscher et al. 2005; Bieda, Hoffmann, and 
Boller 2001; Beimforde et al. 2008; Contreras-Galindo et al. 2015; Young and Bieniasz 
2007; Hanke, Hohn, and Bannert 2016; Dewannieux et al. 2006; Dube et al. 2014). 
 
In the field of HERV-K biology, the Np9 protein has been of particular interest in 
view of its potential to function as an oncogene.  Indeed, Np9 has been shown to control 
cellular signal transduction pathways that modulate expression of growth genes such as 
Notch, Akt, Wnt/ß-catenin, and Myc (Chen et al. 2013; Denne et al. 2007; Armbruester 
et al. 2004).  Further, it has been shown to interact with the promyelocytic leukemia zinc 
finger tumor suppressor (Denne et al. 2007).  In the Notch pathway, Np9 has been 
shown to interact with Numb, and has been thought to perhaps stimulate Notch 
signaling via this interaction, although the details have remained quite unclear 
(Armbruester et al. 2004).  Here, we offer strong evidence that reducing the expression 
of Np9 decreases the cell viability of NCCIT cells, especially when they are challenged 
by serum starvation or chemotherapeutic agents.  The effect is primarily mediated 
through apoptosis, although the mechanistic effect of combining the cisplatin agent with 
 47 
Np9 knock-down remains unclear.  Perhaps most remarkably, we find using wound 
healing assays that Np9 is vital for the proliferation/invasion phenotype, further 
strengthening our observations that Np9 is important for the growth and likely oncogenic 
properties of teratocarcinoma cells.   
 
Teratocarcinoma is often a treatable disease, but the treatment regimens are 
often quite toxic.  Furthermore, the relapse rate is high in advanced stage disease 
(Winter and Albers 2011; Price and Peters 1992; Malavalli, Karra, and Muniyappa 
2013). Here we show that a reduction in Np9 sensitizes NCCIT cells to the clinically 
important chemotherapeutic agents bleomycin and cisplatin. Therefore, our data would 
suggest that targeting Np9 in teratocarcinoma will lead to better outcomes if proper 
drugs/delivery mechanisms can be obtained.  As HERV-K and Np9 have also been 
implicated in other malignancies (Löwer et al. 1993; Büscher et al. 2006; Bieda, 
Hoffmann, and Boller 2001; Seifarth et al. 1998; Muster et al. 2003; Contreras-Galindo 
et al. 2012, 2008; Gonzalez-Hernandez et al. 2012; Contreras-Galindo et al. 2013), it is 
certainly possible that targeting Np9 may sensitize these other cancers to 
chemotherapeutic agents.  Taken together, Np9 appears to be a key protein propelling 
teratocarcinoma viability and a potentially interesting target for future therapeutics.   
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Materials and Methods 
 
Cell lines and cell culture 
 
The teratocarcinoma cell line NCCIT was obtained from ATCC and cultured in 
RPMI (Thermo Fisher Scientific (TFS), catalog #11875-093), supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin (P-S), at 37°C in a 5% CO2 cell 
culture incubator. The medium was changed every 2 to 3 days. Cells were cultured in T-
75 Falcon Tissue Culture Treated Flasks (Fisher Scientific, catalog #353112) until 75% 
confluent and split with TrypLE Express (TFS, catalog #12604013) for 5 min in the 37°C 
incubator. Cells were re-suspended in RPMI supplemented with 10%FBS and 1% P-S. 
Cells were counted with Countess Automated Cell Counter (TFS) using Countess™ 
Cell Counting Chamber Slides (TFS, catalog #C10228). 
 
CRISPR/Cas9 plasmid construct and transfection 
 
The CRISPR/Cas9 guide RNAs were designed using the online CRISPR Design 
Tool (http://crispr.mit.edu) to specifically target HERV-K Np9. The Np9 guide RNAs 
(gNp9-1: gcatcatggcccgttctcga; gNp9-2: ggttttgtcgaaaagaaaag) were cloned into the 
pSpCas9(BB)-2A-Puro (pX459) V2.0 plasmid. The pSpCas9(BB)-2A-Puro (pX459) V2.0 
was a gift from Feng Zhang (Addgene, plasmid #62988) (Supplementary Figure 2.1). As 
a control, a scramble sgRNA (gScr: gagatcgagtgccgcatcac) cloned into the pX459 
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plasmid was used; the scramble plasmid construct was kindly provided by Dr. Xiaoyan 
Jia from the Univeristy of Michigan.  
 
NCCIT cells were seeded at a density of 1,000,000 cells per well in a CytoOne 6-
well tissue culture plate (USA Scientific, catalog # CC7682-7506) and grown for 24 
hours. For transfection of pX459 constructs, we incubated FuGENE® HD transfection 
reagent (Promega, catalog #E2311) with OPTI-MEM reduced serum medium (TFS, 
catalog #31985088), and 500 µg of each plasmid was incorporated at a 1:6 ratio 
(DNA:Transfection reagent) for 30 min at room temperature before being introduced into 
cells. After a 24 hour transfection with sgRNAs, the medium was changed to RPMI 
supplemented with 2 µg/mL puromycin (Sigma, catalog #P8833) for selection, and the 
NCCIT cells were selected for 3 days and then cultured in RPMI for 2 days to recover. 
After 2 days of recovery, the NCCIT clones were transfected with two additional rounds 
of CRISPR/Cas9 constructs. As there are hundreds of copies of Np9 scattered around 
the genome, some with slightly different sequences, CRISPR/Cas9-mediated genome 
editing results in knock-down, rather than a knock-out cell line.  
 
Immunoblot analysis of Np9 knockdown 
 
NCCIT cells were treated with 0.3 µM epoxomicin (Millipore, catalog #324800) for 
24 hours to allow for the stabilization of Np9. NCCIT cells were collected with a cell 
scraper and lysed in cold RIPA Buffer (Sigma, catalog #R0278) supplemented with 
cOMPLETE  protease inhibitor cocktail (Roche, catalog # 11697498001). Protein lysates 
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(33 µg protein per sample) were separated in Bio-Rad 4-20% Mini-PROTEAN® TGX 
gels (Bio-Rad, catalog #4561094). Proteins were transferred to 0.45 µm pore size 
polyvinylidene difluoride membranes (PVDF) (Millipore, catalog # IPVH00010), 
incubated with anti-Np9 rat monoclonal antibody 10B1 (1:25) overnight at 4°C, and then 
incubated with rabbit anti-rat secondary antibody (1:5000) (Invitrogen, catalog #619520) 
(Heyne et al. 2015). The anti-Np9 rat monoclonal antibody was kindly provided by Dr. 
Klaus Römer from the University of Saarland Medical Center. Membranes were 
incubated with SuperSignal femto chemiluminescent substrate (TFS, catalog #34095). 
As a loading control, the PVDF membrane was incubated with mouse anti-GAPDH 
(1:10000) (Santa Cruz, catalog #166545), and then incubated with horse anti-mouse 
secondary antibody (1:10000) (CST, catalog #7076S). We used ImageJ to analyze the 
intensity of the Np9 signal to determine the efficiency of the CRISPR/Cas9-mediated 
gene KD.   
 
Starvation and MTT assay 
 
To synchronize and starve the teratocarcinoma cells, the NCCIT cells were 
seeded at a density of 1000 cells per well in a Falcon 96-well tissue culture plate 
(Fisher, catalog #353072) and cultured in 100 µL RPMI supplemented with 1% P-S for 
24 hours. After 24 hours, the medium was removed and changed to 100 µL full RPMI 
medium (time 0). At time 0, each well was treated with 10 µL MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenytltetrazolium Bromide) (5 mg/mL) for 3 hours, and then 
100 µL of solubilization solution (10% SDS in 0.01M HCl) was added to each well to 
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stop the reaction. The plate was then wrapped in aluminum foil and incubated in a 
37°C/5% CO2 incubator overnight, and was analyzed the following day with a Tecan 
GENios plate reader. Days 4, 5 and 6 were done in similar manner and optical density 
(OD) measurements were obtained. The optical density measurements were used to 
calculate percent cell viability, days 4, 5 and 6 were divided by OD obtained on day 0, 
resulting number was multiplied by 100 to determine percentage viability.  
 
Bleomycin and cisplatin treatments and MTT assay 
 
NCCIT cells were seeded at a density of 1000 cells per well in Falcon 96-well 
tissue culture plates (Fisher, catalog #353072) and cultured in full RPMI media for 24 
hours. At 24 hours, the media was changed to media supplemented with 5, 15, 30, 60 
or 120 µg/mL bleomycin (Cayman Chemical, catalog #13877) or 0.1, 0.5, 1, 15, 15 
µg/mL cisplatin (Cayman Chemical, catalog #13119) and the plates were cultured for 48 
hours. MTT assay was performed at 0 and 48 hours post-treatment. Calculations were 
done in a similar manner as previously described.  
 
Cell Cycle Analysis 
 
NCCIT cells were seeded at a density of 220,000 cells per well in a 6-well 
CytoOne tissue culture plate (USA Scientific, catalog #CC7682-7506), cultured in RPMI, 
and the media was changed every 24 hours. The cells were trypsonized with TrypLE 
Express, collected and centrifuged at 700 rpm for 5 mins. The cell pellet was washed 
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once with 1X phosphate buffered saline (PBS) (TFS, catalog #10010023) and fixed with 
70% ice-cold ethanol for 30 mins on ice. The fixed cells were washed with 1X PBS, re-
suspended with FxCycle PI/RNase staining solution (Molecular Probes, catalog 
#F10797), and stained in the dark for 30 mins prior to analysis. The cells were analyzed 
with a Bio-Rad ZE5 cell analyzer at the University of Michigan Flow Cytometry Core.  
 
Flow cytometry for activated caspase 3/7 apoptosis assay 
 
NCCIT cells were seeded at 150,000 cells per well in a 6-well CytoOne tissue 
culture plate (USA Scientific, catalog #CC7682-7506) and cultured in full RPMI medium 
for 24 hours. After 24 hours, the medium was changed to mock treatment (full RPMI 
media), RPMI medium containing 30 µg/mL bleomycin or 1 µg/mL cisplatin, or cells 
were placed under serum starvation conditions (serum free media). After 24 hours, the 
cells were trypsonized with TrypLE Express, collected, washed with 1X PBS (PBS), and 
stained with CellEvent Caspase 3/7 Green Detection Reagent (TFS, catalog #C10427) 
for 60 mins; for the last 5 mins the cells were stained with SYTOX® AADvanced Dead 
Cell Stain (TFS, catalog #C10427). Caspase 3/7 analysis was performed with a Sony 
SH800 Cell Sorter at the University of Michigan Flow Cytometry Core. 
 
Wound closure assay 
 
Wound closure assay was performed with NCCIT Np9 CRISPR cells or with 
control NCCIT scramble cells. The tissue culture plates were treated with 0.001% poly-
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L-lysine solution (Sigma, catalog # P8920) and stored at 4°C until use. NCCIT cells 
were seeded at a density of 200,000 cells per well in a 12-well CytoOne tissue culture 
plate (USA Scientific, catalog #CC77682-7512) and cultured in RPMI for 24 hours. After 
24 hours, each well was scratched linearly with a pipette tip, and images were captured 
at 0 and 24 post-scratch. To determine percent migration, images were measured used 
to measure the width of the wound through the entire length of the wound within the 
image using the NIS Elements image software. The percent migration was calculated by 
dividing the width of the wound at time 24 with time 0 and then multiplying by 100 to 
obtain percentage of migration.  
 
Np9 complementation plasmid construct 
 
Re-introduction of Np9 into NCCIT Np9 KD cells was performed using the 
piggyBac transposon system. Np9 complementation was performed with the PB-CAG-
Np9-mCherry transposon, and the PB-CAG-H2B-mCherry transposon was used as the 
control. NCCIT cells (scramble, Np9 KD #8 and #9) were seeded at a density of 
1,000,000 cells per well in a CytoOne 6-well tissue culture plate. NCCIT scramble 
control cells and NCCIT Np9 KD cell clones 8 and 9 were co-transfected with PB-CAG-
H2B-mCherry transposon plasmid and pCAG-PBase transposase plasmid at a 1:1 ratio 
as a control. NCCIT Np9 KD clones 8 and 9 were co-transfected with PB-CAG-Np9-
mCherry transposon and pCAG-PBase transposase plasmid at a 1:1 ratio. Twenty-four 
hours post transfection, the cells were selected for mCherry using a Sony SH800 cell 
sorter, and allowed to grow for a week in full media. The cells were selected a second 
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time for mCherry a week after the first selection to ensure that the mCherry expressing 
constructs were stably integrated. These cells were used for a wound closure assay 
done in a similar manner as previously described. 
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D) 
 
 
 
 
 
 
 
Figure 2.1 Reduced expression of Np9 in NCCIT teratocarcinoma cells increases sensitivity to 
environmental stress. (A) NCCIT cells were either transfected with a scramble CRISPR/Cas9 
system or Np9 CRISPR/Cas9 guide RNAs. After three rounds of transfection with CRISPR/Cas9 
Np9 guides, Clones 8 and 9 were selected, and the level of Np9 was shown to be reduced by 80% 
and 20%, respectively; Np9 densitometry was analyzed with ImageJ. (B) NCCIT scramble control 
and Np9 KD cells were cultured in full media and viability was measured with MTT assay (n=6 for 
each cell line). Reduced expression of Np9 had a limited effect on the viability of the teratocarcinoma 
cells. (C) NCCIT scramble control and Np9 KD cells (n=4 for each cell line) were cultured in full 
media for 48 hours, and media was changed every 24 hours. Cell cycle analysis was performed with 
the Bio-Rad ZE5 cell analyzer. Reduced expression of Np9 had a very modest effect on the 
distribution of the cell cycle in teratocarcinoma cells. (D) NCCIT scramble control and Np9 KD cells 
were cultured in serum free media (environmental stress) for 24 h, and after 24 h media was 
changed to full media, and viability was measured with MTT assay (n=8 for each cell line). The 
reduced expression of Np9 increased sensitivity to environmental stress and resulted in fewer viable 
cells.  T bars denote the standard deviations of the means; P values were determined using student 
t-test analysis. ns not significant, *P<0.05, **P<0.001, ***P<0.0001. The Np9 CRISPR/Cas9 guide 
RNAs were designed and provided by our collaborators, Dr. Orly Reiner and Dr. Tamar Sapir. The 
scramble CRISPR/Cas9 guide RNA was kindly provided by Dr. Xiaoyan Jia. Dr. JoAnn Sekiguchi 
provided reagents necessary for cell cycle analysis.       
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Figure 2.2 Reduced expression of Np9 in NCCIT teratocarcinoma cells increases sensitivity to 
chemical stress. NCCIT scramble control and Np9 KD cells were cultured in regular media for 24 h 
(n=4 for each cell line). The following day, the media was changed to mock treatment (full media) or 
media supplemented with (A) bleomycin (30 µg/mL) or (B) cisplatin (1 µg/mL) and cultured for 48 h; 
at 48 h viability was measured with MTT assay. Reduced expression of Np9 resulted in increased 
sensitivity to bleomycin or cisplatin treatment with decreased viability of NCCIT cells. T bars denote 
the standard deviations of the means; P values were determined using student t-test analysis. ns not 
significant, *P<0.05, **P<0.001, ***P<0.0001 
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Figure 2.3 Reduced expression of Np9 in NCCIT teratocarcinoma cells increases sensitivity to 
chemical stress, resulting in apoptotic cells. NCCIT scramble control and Np9 KD cells were 
cultured in full media. The following day media was changed to either mock treatment (full media) or 
treatment (30 µg/mL bleomycin). After 24 h of treatment, the cells were stained with SYTOX 
AADvanced and Caspase 3/7 and apoptosis analysis was performed with a Sony SH800 Cell Sorter. 
Np9 KD clones 8 and 9 were naturally more apoptotic than scramble control cells: 20 and 25% 
compared to 6%, respectively. The reduction of Np9 expression in NCCIT cells increased sensitivity 
to bleomycin, with increased apoptosis in Np9 KD clones 8 and 9 compared to scramble control 
cells: 71% and 50% compared to 40%, respectively. The percent of apoptotic cells represented in 
the table was calculated from the bottom right and upper right quadrants, with the bottom right 
quadrant being early stage apoptotic cells and the upper right quadrant being late stage apoptotic 
cells.  
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Figure 2.4 Np9 is essential for cell migration and wound closure. (A) NCCIT scramble control 
and NCCIT Np9 KD clones 8 and 9 were used for the migration assay. A total of 200,000 cells for 
each cell type were transferred into a 12-well plate. The following day, a scratch was created down 
the middle, and pictures were taken at time 0 and at 24 hours. The images are representative of 3 
independent experiments done in duplicate. Scales bars, 100 µm. (B) The wound was measured at 
time 0 and at 24 hours. The percent of migration was plotted over time 0. The measurements are 
representative of 3 independent experiments done in duplicate. The width of the wounds was 
measured in each image and totaled for scramble CT (n=26), KD #8 (n=27), and KD #9 (n=28). The 
reduction in the expression of Np9 in NCCIT cells resulted in reduced cell migration post-wound as 
compared to scramble control cells. T bars denote the standard deviations of the means; P values 
were determined using student t-test analysis. ***P<0.0001 
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Figure 2.5 Re-introduction of Np9 into teratocarcinoma cells rescues the migration 
phenotype. (A) NCCIT scramble, Np9 KD clones 8 and 9 with H2B-mCherry control clones and 
NCCIT Np9 KD clones 8 and 9 with Np9-mCherry clones were used for the migration assay. A total 
of 200,000 cells for each cell type were transferred into a 12-well plate. The following day, a scratch 
was created down the middle, and pictures were taken at time 0 and at 24 hours. The images are 
representative of 2 independent experiments done in duplicate. Scales bars, 100 µm. (B) The wound 
was measured at time 0 and at 24 hours. The percent of migration was plotted over time 0. The 
measurements are representative of 2 independent experiments done in duplicate. The width of the 
wound was measured for each sample: scramble CT-H2B-mCherry (n=83), Np9 KD #8 H2B-
mCherry (n=135), Np9 KD #8 Np9-mCherry (n=156), Np9 KD #9 H2B-mCherry (n=160), and Np9 
KD #9 Np9-mCherry (n=145). The re-introduction of Np9 into Np9 KD cells rescued the migratory 
phenotype of the NCCIT cells almost to the level of the scramble control, and in the case of Np9 KD 
clone 8 complemented with Np9-mCherry, the re-introduction of Np9 resulted in faster migration 
compared to the scramble control. T bars denote the standard deviations of the means; P values 
were determined using student t-test analysis. ns not significant, ***P<0.0001. The mCherry 
constructs were made by Drs. Tamar Sapir and Orly Reiner at the Weizmann Institute.  
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Supplementary Figures 
 
 
Supplementary Figure 2.1 A map of pSpCas9(BB)-2A-Puro (PX459) V2.0 plasmid. BsbI 
recognition sites were used to replace the cassette with the cDNA sequence for the Np9 guide 
RNAs. Image taken from Addgene.com. 
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Supplementary Figure 2.2 An illustration of the 
PiggyBac Transposon system.  The PiggyBac (PB) 
transposon is a moveable genetic element that 
transposes between the vector and chromosome 
through a cut and paste mechanism. The PB 
transposase (Red) recognizes the transposon 
specific inverted terminal repeats (Blue) located at 
both ends of the vectors that flank the transgene 
(Orange), cuts the PB transposon, and integrates the 
contents into TTAA chromosomal sites. The PB 
system has been shown to have the highest 
transposition activity in mammalian cells.  Image 
adapted from Biocat.com. 
 
 
 
A) ATGAACCCATCGGAGATGCAAAGAAAAGGGCCTCCGCGGAGATGTCTGCAGGT
GTACCCAACAGCTCCGAAGAGACAGCGACCATCGAGAACGGGCCATGATGAC
GATGGCGGTTTTGTCGAAAAGAAAAGGGGGAAATGTGGGGAAAAGCAAGAGA
GATCAGATTGTTACTGTGTCTGTGTAGAAAGAAGTAGACATAGGAGACTCCATT
TTGTTATGTGC 
 
B) MNPSEMQRKGPPRRCLQVYPTAPKRQRPSRTGHDDDGGFVEKKRGKCGEKQER
SDCYCVCVERSRHRRLHFVMC 
 
Supplementary Figure 2.3 HERV-K 101 Np9. (A) The HERV-K 101 np9 nucleotide sequence was 
the reference sequence used in the design of the Np9 CRISPR guide RNAs, and the np9 gene was 
cloned into the PB-CAG-mCherry vector for the complementation experiments. (B) The HERV-K 101 
Np9 amino acid sequence. 
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Chapter 3  
 
DISCUSSION 
 
Prior to the sequencing of the human genome, it was estimated that our genome 
consists of a hundred thousand or more genes, but that was proven to be an over-
estimation. The human genome consists of only twenty to twenty-five thousand genes 
that make up 1.1% of the DNA sequence, with the remaining 98.9% originally being 
falsely labeled “junk” DNA (Lander et al. 2001; Collins et al. 2004; Chial 2008). The 
large bulk of genetic material was considered “junk” because it had no known biological 
function. However, we now know that some of the “junk” sequences can serve as 
regulatory elements that are integral to biological function (Maston, Evans, and Green 
2006; Plank and Dean 2014). In addition, transposable elements make up about 42% of 
the genome (Lander et al. 2001). These transposable elements consist of endogenous 
retroviruses characterized by the presence of long terminal repeats, and short 
interspersed nuclear elements (SINES) and long interspersed nuclear elements (LINES) 
that do not have LTRs; LINES can encode reverse transcriptase. HERVs are LTR-
positive retroelements that make up 8% of the human genome (Lander et al. 2001; 
Bannert and Kurth 2004; Bannert and Kurth 2006; Weiss 2006; Subramanian et al. 
2011).  
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Interestingly, the existence of HERVs in the human genome is the result of 
ancient infections by exogenous retroviruses and subsequent integration of retroviral 
elements into germ cells; these proviral sequences have been inherited in the 
Mendelian fashion (Nelson et al. 2003; Jern and Coffin 2008; Subramanian et al. 2011). 
HERVs are distributed across the genome and the distribution has been suggested to 
be non-random; it has been reported that they migrated to regions of chromosomes with 
high levels of heterochromatin, thus increasing their chances to be retained in the host 
genome (Kurdyukov et al. 2001). These proviral elements have accumulated insertions, 
mutations, and deletions in the open reading frames of pertinent viral genes, which 
rendered them incapable of replication (Hughes and Coffin 2004). While most HERVs 
are defective, a limited number have retained the potential to produce viral products 
such as viral particles, viral transcripts, and viral proteins (Löwer et al. 1993; Tönjes et 
al. 1996; Seifarth et al. 1998; Johnston et al. 2001; Sugimoto et al. 2001; Bieda, 
Hoffmann, and Boller 2001; Wang-Johanning et al. 2001; Yi et al. 2001; Ruda et al. 
2004).    
 
Evidence thus far suggests that the expression of HERV products can either be 
beneficial in biological processes, a causative factor in human malignancies, or an 
innocent bystander in disease states. Most HERVs entered primates 60 to 30 million 
years ago, and have been rendered inactive due to the accumulation of mutations 
(Bannert and Kurth 2004). However, the most transcriptionally active family and one of 
the most recent entrants into the human genome is the HERV-K (HML-2) subfamily 
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(Tönjes et al. 1996; Seifarth et al. 1998; Barbulescu et al. 1999; Okahara et al. 2004; 
Johnston et al. 2001; Sugimoto et al. 2001; Wang-Johanning et al. 2001; Yi et al. 2001; 
Ruda et al. 2004). The abundance of the HERV-K (HML-2) subfamily in modern-day 
humans is a result of replication, re-infection, and recombination during human 
evolution (Belshaw et al. 2004). Even though to date there is no evidence of an 
infectious and replicative HERV-K (HML-2) virus in modern humans, this subfamily is 
considered to be “active” because the proviruses can produce viral like particles, 
express viral transcripts, and code for viral proteins (Löwer et al. 1993; Seifarth et al. 
1998; Bieda, Hoffmann, and Boller 2001; Muster et al. 2003; Büscher et al. 2005). 
Futher, HERV-K (HML-2) can be passaged from one cell to another (Contreras-Galindo 
et al. 2015). Therefore, it comes as no surprise that there has been a great deal of 
interest in HERVs in general, and HERV-K in particular, and their potential function in 
human biology and disease. 
 
HERV expression beneficial for development of the placenta 
 
Considering that HERVs make up a sizeable portion of the human genome, it 
has been a topic of discussion whether these ancient germ line infections were retained 
because they performed, or perform, useful biological functions. Indeed, it has been 
found that the envelope protein from the HERV-W, HERV-FRD, and HERV-R families 
has been linked to the development of human placenta; these proteins are termed 
syncytin-1, syncytin-2, and ERV-3 Env, respectively (Bolze, Mommert, and Mallet 
2017). Some of the critical aspects of placenta development include fusion, proliferation, 
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angiogenesis, immune tolerance, and tissue survival. These envelope glycoproteins 
have been shown to have fusogenic and immunosuppressive properties, thus 
supporting essential functions of placenta development (Malassiné et al. 2007). 
Syncytins have been shown to have similar roles in the placental development of mice 
(Gong et al. 2007).   
 
HERV expression linked to neurological and autoimmune diseases 
 
HERVs have been linked to autoimmune diseases such as multiple sclerosis 
(MS) and sporadic amyotrophic lateral sclerosis; the role of HERV in MS was described 
previously. Sporadic amyotrophic lateral sclerosis is a progressive neurodegenerative 
disease, and is usually fatal, except in the case of some ALS patients with HIV infection; 
the anti-retroviral therapy used to treat HIV infection has sometimes been shown to 
reverse ALS-like syndromes (Bowen et al. 2016; Alfahad and Nath 2013; Orsini et al. 
2012; Calza et al. 2004; Casado et al. 1997; Galassi et al. 1998; Verma, Ziegler, and 
Kepes 1990). Reverse transcriptase activity has been detected in the blood and brain 
tissue of ALS patients, prompting the search for the exogenous retroviruses responsible 
(MacGowan et al. 2007; McCormick et al. 2008; Steele et al. 2005; Viola et al. 1975). 
However, the search for exogenous retroviruses that can be linked to ALS has not been 
successful. Interestingly, HERV-K was found to be expressed in the neurons of ALS 
patients but not in the neurons of healthy individuals, and the expression of HERV-K 
envelope protein was shown to cause the retraction and beading of neurites (Douville et 
al. 2011; Li et al. 2015). The expression of HERV-K Env caused a decrease in cell 
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numbers, thus suggesting that the envelope protein could contribute to neurotoxicity 
and neuronal death (Li et al. 2015). Furthermore, the expression of HERV-K Env in the 
embryonic mouse brain resulted in the degeneration of motor neurons (Li et al. 2015). 
Thus, mounting evidence suggests that HERV-K expression might play a role in the 
pathophysiology of ALS, although this remains to be clarified.   
 
HERVs are also believed to be pathogenic in rheumatic diseases such as 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). RA and SLE are 
very complex diseases, and the induction of disease requires genetic susceptibility, 
environmental factors, and inopportune circumstances (Tugnet et al. 2013). It is 
suggested that HERVs induce RA and SLE through immune dysregulation and 
molecular mimicry. The theory of molecular mimicry is that a foreign protein that shares 
sequence homology to self-peptides can result in self-reactive cells, such as B or T cells 
(Tugnet et al. 2013). HERV-K has been detected in the plasma of RA patients, with 
higher titers observed in patients with active disease; RA patients exhibited elevated 
levels of HERV-K gag expression as compared to healthy controls (Freimanis et al. 
2010). It is thought that HERV expression can generate an immune response and 
induce disease through molecular mimicry, providing a continuous source of antigen for 
the self-reactive immune cells. HERV antigens are similar to exogenous viral antigens 
that may cross-react with self-antigens, and therefore could elicit pathological antibodies 
(Tugnet et al. 2013). As an example, the gag protein of HTLV-related endogenous 
sequence-1 (HRES-1) has sequence homology and cross-reactivity with the U1-small 
nuclear ribonucleoprotein (U1-snRNP); the U1-snRNP is an autoantigen, and a target of 
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autoreactive B and T cells in rheumatic diseases such as SLE (Perl et al. 1995). In a 
study, it was shown that 50% of SLE patients had anti-HRES-1 antibodies that bound to 
the U1-snRNP autoantigen, while antibodies were only detected in 3.6% of healthy 
individuals, suggesting that the expression of the HERV protein triggered an 
autoimmune response directed against U1-snRNP (Perl et al. 1995). Normally, self-
reactive B and T cells are eliminated to ensure that the immune system does not attack 
itself. However, in the case of SLE patients, dysregulation of apoptosis allows for the 
self-reactive cells to bypass deletion (Emlen, Niebur, and Kadera 1994). Taken 
together, it is possible that HERVs induce immune reactivity in rheumatoid diseases.    
 
HERV expression and cancer 
 
As noted previously, HERV-K has been implicated in different human 
malignancies such as breast cancer, prostate cancer, ovarian cancer, melanoma, germ 
cell tumors, leukemia, and lymphomas (Seifarth et al. 1998; Wang-Johanning et al. 
2001; Bieda, Hoffmann, and Boller 2001; Büscher et al. 2005; Löwer et al. 1993; Muster 
et al. 2003; Contreras-Galindo et al. 2012; Contreras-Galindo et al. 2013, 2006; 
Contreras-Galindo et al. 2008; Contreras-Galindo, Almodóvar-Camacho, et al. 2007; 
Contreras-Galindo, López, et al. 2007). High level of HERV-K transcripts can be seen in 
disease states but generally not in healthy individuals, and the expression of HERV-K 
proteins appears to be particularly restricted to malignancies (Schmitt et al. 2015). The 
HERV-K accessory proteins Np9 and Rec have been suggested to be oncoproteins 
(Chen et al. 2013; V. Armbruester et al. 2004; Kaufmann et al. 2010; Denne et al. 2007; 
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Galli et al. 2005; Gross et al. 2011). Most HERVs are silenced because most have 
taken residence in areas of the genome that are hyper-methylated. However, global 
hypo-methylation has been seen in some cancers and, therefore, the activation of 
HERV-Ks result from this process (Mullins and Linnebacher 2012). It is important to 
note that the activation or expression of HERV-K and HERV-K products has been seen 
in all the human malignancies noted above.  
 
Interestingly, the HERV-K Env protein has been shown to be over-expressed in 
breast cancer cells (BC cells) and tissues (Zhao et al. 2011). In a recent study, 
investigators knocked-down the expression of HERV-K Env in breast cancer cells, 
which hindered BC cell proliferation, migration, and invasion; knocking-down HERV-K 
Env prevented BC cells from forming tumors, thus preventing metastasis (Zhou et al. 
2016). The downregulation of HERV-K blocked the expression of Ras, p-RSK, and p-
ERK, which are tumor associated genes, and the re-introduction of HERV-K Env in 
HERV-K Env knock-down BC cells resulted in the restoration of the Ras/Raf/MEK/ERK 
signaling pathway (Zhou et al. 2016). These findings led the investigators to conclude 
that the activation of the HERV-K Env protein is essential for the tumorigenesis and 
metastasis of breast cancer cells (Zhou et al. 2016).  
 
The expression of HERV-K Env, Rec and Np9 proteins has been detected in 
melanomas and melanoma cells but not in melanocytes (Büscher et al. 2005, 2006), 
and the activation of HERV-K has been implicated in the malignant transformation of 
melanoma cells (Serafino et al. 2009). Furthermore, UV irradiation of normal human 
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epidermal melanocytes induced the expression of HERV-K rec and np9 transcripts; the 
rec and np9 transcript levels remained unchanged in UV irradiated melanoma cells, 
suggesting that Rec and Np9 could play a functional role in melanoma formation 
(Reiche, Pauli, and Ellerbrok 2010).  
 
HERV-K 111 
 
In recent years, during our study of the activation of HERV-K by the HIV TAT 
accessory protein, we discovered HERV-K (HML-2) RNA sequences in HIV-1 patients 
that were not present in the recently annotated human genome assembly. We termed 
the newly-discovered HERV-K (HML-2) type 1 virus K111. The K111 virus inserted itself 
into the genome of the hominid lineage prior to the split between chimpanzees and 
humans. This virus exists in chimpanzees as a single copy (none in gorillas or lower 
primates), but can be found in multiple copies in the modern day human, and copies of 
this virus are spread across the centromeres of 15 chromosomes. During the evolution 
of humans, the virus expanded in copy numbers through a process resembling 
homologous recombination. The expansion of the K111 viruses suggests that 
recombination took place between the centromeres of various chromosomes during 
human evolution. From our investigation, we saw a significant variation in the sequence 
of K111 proviruses in each centromere. To date, it is still not clear how many copies of 
K111 exists in the human genome, but it appears that there are between 100 to one 
thousand copies. However, most of the viral genes of K111 are mutated and cannot 
produce viable viral products, with one exception: the K111 virus contains an intact 
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open reading frame for the Np9 protein and variants of Np9. For this reason, we were 
intrigued to investigate the reason for retaining the coding sequence for the accessory 
protein. Could the HERV-K accessory protein Np9 play a role in development or 
promote oncogenesis, or does it exist as a simple bystander in health and disease?  
 
The implication of Np9 in cancer and its disruptive influence on cell signaling 
pathways 
 
The activation and inactivation of cell signaling pathways are highly modulated; 
any perturbations in the cell signaling pathways can be detrimental, and lead to 
uncontrolled cell proliferation and tumorigenesis. In recent years, some light has been 
shed on the possible functions of Np9 and Rec in human biology in terms of interacting 
partners, and their role in different cell signaling pathways.  
 
As noted previously, the physical interaction between Rec and Np9 with the 
promyelocytic zinc finger protein results in the de-repression of c-myc, and improper 
regulation of c-myc can result in over-proliferative cells and promote oncogenesis 
(Denne et al. 2007). Also, Np9 has been shown to interact with LNX (ligand of numb 
protein X), an E3 ubiquitin ligase that targets Numb in the Notch signaling pathway 
(Armbruester et al. 2004). Further, Np9 can activate ß-catenin, ERK, Akt, and Notch1, 
and promote the growth of human leukemia stem/progenitor cells (Chen et al. 2013). 
The interaction between Np9 and repressive elements, such as PLZF and LNX/Numb, 
alters the normal biological function of the repressive elements, and results in the 
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activation of signaling pathways (Denne et al. 2007; Armbruester et al. 2004). 
Furthermore, Np9 has been shown to activate pro-proliferative cell signaling pathways, 
such as Wnt/ß-catenin and Notch1 (Armbruester et al. 2004; Chen et al. 2013). 
Therefore, we set out to explore the role of Np9 in other malignancies.  
 
The role of Np9 in teratocarcinoma cell viability   
 
To further examine the role of Np9 in cancer, we compared the expression level 
of np9 transcripts in different human cancer cell lines that were thought to be associated 
with HERV-K (Figure 3.1). Certain of these cell lines have also been shown to produce 
HERV-K (HML-2) VLPs. Specifically, the cell lines that we studied were derived from 
human breast cancer, prostate cancer, germ cell tumors (ovarian and testicular), and 
melanoma. Even though np9 transcripts were found in all the cancer cell lines tested, 
they were more highly expressed in some of the breast cancer cell lines, melanoma cell 
lines, and germ cell tumor cell lines. The expression of np9 transcripts varied among 
germ cell tumor cell lines, with a higher expression level in testicular derived germ cell 
tumor cell lines than in ovarian derived germ cell tumor cell lines.  
 
Teratocarcinoma is a testicular germ cell tumor that has been shown to be more 
prevalent in young men, which is concerning considering the chances of relapse and 
the toxicity of treatment regimens. The treatment regimens used for this cancer can be 
quite effective even in disseminated disease. However, relapse can occur in individuals 
with late stage disease a year after concluding treatment. The treatment regimen 
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usually consists of bleomycin and cisplatin, both of which are highly toxic 
chemotherapeutic agents. Considering that teratocarcinoma occurs in young men, long-
term remission and fertility are also major concerns and development of less toxic and 
more effective treatment regimens is necessary. We therefore considered whether the 
expression of Np9 in testicular germ cell tumor cells was the result of the disease, was 
simply a disease marker, or whether Np9 expression promotes tumorigenesis.  
 
We hypothesized that Np9 promoted tumorigenesis in NCCIT teratocarcinoma 
cells, a cell line that express viral like particles containing K111. However, the reduction 
of Np9 in NCCIT teratocarcinoma cells using CRISPR/Cas9 mediated genome editing 
resulted in only modest alterations to the viability of the cells, which was quite puzzling. 
It is possible that full depletion of Np9 is necessary to see very significant hindrance to 
the viability of NCCIT cells. However, tools necessary to deplete the genome of all Np9 
and its variants are not available. Also, it is possible that the function of Np9 in NCCIT 
teratocarcinoma cells is not one of promoting proliferation but that of survival. When we 
subjected the teratocarcinoma cells to environmental stress in conjunction with reduced 
Np9 expression, there was marked reduction in cell viability. The striking reduction in 
viability in the Np9 KD cells compelled us to question the effect of chemotherapeutic 
agents on the KD cells. We reasoned that if Np9 played a role in the survival of NCCIT 
cells, then the reduction of Np9 would increase teratocarcinoma cell sensitivity to 
bleomycin and cisplatin. We indeed found that the Np9 KD cells were more susceptible 
to bleomycin or cisplatin treatment, and the response to the chemotherapeutic agents 
was dose-dependent. The reduction of Np9 worked synergistically with the 
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chemotherapeutic agents, thus reducing cell viability. Further, treating NCCIT cells with 
bleomycin resulted in the increased activation of caspase dependent apoptotic cell 
death in Np9 KD cells; the mechanism of increased cell death is still unclear in terms of 
cisplatin treatment.  
 
The studies up to that point were focused the role of Np9 in teratocarcinoma cell 
viability. We decided to look at another crucial hallmark of cancer, which is the migration 
of cancer cells. The migration of cancer cells is an important aspect of tumor 
progression; metastasis is a result of cancer cells migrating from a centralized region to 
adjacent regions, thus increasing the level of difficulty in the clearance of circulating 
cancer cells even after primary tumor removal. Impressively, reduced expression of Np9 
greatly hindered the migration ability of the NCCIT cells, and the re-introduction of Np9 
in KD cells rescued the migration phenotype. 
  
If further studies in vivo and in vitro continue to demonstrate that Np9 expression 
plays a pivotal role in the invasiveness of the cancer cells it would prompt a search for 
an agent that would inactivate Np9 and be used as part of treatment regimens. 
However, it is important to stress the difficulty in targeting HERVs in the human 
genome. Considering that 8% of the human genome consists of HERVs, the first hurdle 
that must be overcome is the complexity of specifically targeting HERVs or HERV 
products. Adding to the complexity is the possibility that insufficient reduction of Np9 will 
lead to therapeutic failure, whereas too much reduction might harm Np9 cellular function 
as discussed in the Appendix. 
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Identifying Np9’s role in different cell signaling pathways in teratocarcinoma cells 
 
Testicular germ cell tumor incidence has increased in the last decade and it is 
the most common solid tumor in young males (Cooper et al. 2008). However, the 
molecular mechanisms of teratocarcinoma formation are still not well understood. 
Aberrant activation of cell signaling pathways is a common event in human tumor 
progression. Investigators attempted to determine if the aberrant cell signaling 
processes give rise to the formation of teratocarcinoma. For example, a study led by 
Jing Hao explored the mechanism and function of the Wnt/ß-catenin signaling pathway 
in the pathogenesis of teratocarcinoma (Zhang et al. 2012). Researchers treated P19 
mouse teratocarcinoma cells with all trans-retinoic acid and a GSK3ß inhibitor to induce 
P19 cell differentiation and activate the Wnt/ß-catenin signaling pathway, respectively. 
In their study, investigators measured P19 cell proliferation by looking at gene 
expression using quantitative RT-PCR, protein expression using Western blotting, and 
cell proliferation using BrDU incorporation. Their results showed that GSK3ß inhibitor 
treatment of P19 teratocarcinoma cells results in the activation of the Wnt/ß-catenin 
signaling pathway, as represented by the nuclear translocation of ß-catenin, the 
upregulated the expression of c-myc and pluripotent-related genes such as oct4, sox2, 
and nanog. Further, GSK3ß inhibition blocked cell differentiation normally induced by 
all-trans retinoic acid. In summary, researchers found that the activation of Wnt/ß-
catenin cell signaling pathway can promote cell proliferation of P19 teratocarcinoma 
cells, and the upregulation of c-myc inhibited differentiation (Zhang et al. 2012).  
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During our studies on the effect of Np9 knockdown in NCCIT teratocarcinoma 
cells, we wanted to determine whether Np9 played a role in cell signaling pathways 
involved in teratocarcinoma. Considering that the Wnt/ß-catenin signaling pathway 
might play a role in teratocarcinoma progression, we investigated whether knocking 
down Np9 in NCCIT teratocarcinoma cells affected the expression of Wnt related 
proteins (Figure 3.2). In the absence of Wnt-signal (off-state), ß-catenin is 
phosphorylated by CK1 and the APC/Axin/Gs3kß complex leads to its ubiquitination and 
subsequent proteasomal degradation. In the presence of Wnt-signal (on-state), ß-
catenin is stabilized and translocated to the nucleus where it binds to LEF/TCF 
transcription factors, displaces co-repressors, and ultimately recruits additional co-
activators to Wnt target genes.  
 
When we knocked down the expression of Np9 in NCCIT teratocarcinoma cells, 
we did not see a difference in the expression of ß-catenin (active form) (Figure 3.2); 
therefore, we concluded that the reduced expression of Np9 has no effect on the Wnt/ß-
catenin signaling pathway. Recent studies have shown that Np9 play a role in the 
MAPK/Erk, c-myc/AKT, and the Notch1 signaling pathways in human leukemia cells 
(Chen et al. 2013). We determined that the reduced expression of Np9 in NCCIT cells 
has no effect on the expression of phosphorylated c-myc or phosphorylated Akt (Figure 
3.2).  
 
We then considered the role of Np9 in other signaling pathways. To begin, we 
looked at the effect of knocking down Np9 in NCCIT cells on the MAPK/Erk signaling 
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pathway, which is involved in cell growth and differentiation. To our surprise, reduced 
expression of Np9 in NCCIT cells resulted in the downregulation of phosphorylated 
Erk1/2 (Figure 3.3A), but it had no effect on Mek1/2 or phosphorylated Mek1/2, which 
are upstream of Erk1/2 (Figure 3.3B), suggesting Np9 expression plays a role in the 
regulation of Erk1/2. The MAPK/Erk signaling pathway controls transcription and cell 
cycle progression through the activation and regulation of MAPK/Erk-related proteins 
such as p90RSK (transcription) and cdc25c (cell cycle progression).  
 
Next, we wanted to determine if knocking down Np9 in NCCIT teratocarcinoma 
cells altered the expression of MAPK/Erk related proteins that regulate transcription and 
cell cycle progression. We saw that the reduced expression of Np9 in NCCIT cells 
downregulated the expression of cdc25c, but the Np9 downregulation had no effect on 
p90RSK (Figure 3.3B). Therefore, we conclude the reduced expression of Np9 results 
in the downregulation of the MAPK/Erk pathway and cdc25c, and can potentially disrupt 
cell cycle progression.  
 
Lastly, we wanted to determine whether the reduced expression of Np9 in NCCIT 
teratocarcinoma cells alter the Notch1 cell signaling pathway. As mentioned previously, 
the Np9 protein interacts with the Notch repressive element LNX/Numb. Therefore, we 
sought to answer whether the reduction in Np9 expression alters the activation of the 
Notch1 pathway. As shown in Figure 3.4, the reduction of Np9 in NCCIT 
teratocarcinoma cells resulted in the upregulation of phosphorylated Numb, which is the 
inactive form that would be subjected to proteasomal degradation. Interestingly, we 
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witnessed a downregulation of MAML-1, a Notch transcriptional co-activator, which 
indicated a downregulation of the Notch pathway. Our attempt at elucidating the 
mechanistic role of Np9 in different signal transduction pathways illustrated that Np9 
may play a role in the MAPK/Erk and in the Notch pathway in teratocarcinoma cells. 
However, the preliminary studies presented here on the role of Np9 in signal 
transduction pathways were not always replicable, and therefore, further studies would 
be necessary to fully to validate the findings. 
 
Conclusion  
 
Evidence thus far suggests that the role of HERVs in human biology, disease 
and malignancy is incredibly complex. HERVs makeup a sizeable portion of the human 
genome and the HERV-K (HML-2) subfamily is one of the most recent entrants into the 
human genome; this subfamily has remained transcriptionally active, and can produce 
viral products. Since our discovery of the HERV-K type 1 virus termed K111 in the 
centromeric region of human chromosomes, we have determined that there are at least 
100 to one thousand copies spread across 15 different human chromosomes. The K111 
virus is highly mutated in almost all viral genes, rendering it incapable of producing a 
replicative virus. However, it retains the open reading frame for the accessory protein 
Np9. We speculated that the coding sequence for Np9 was retained in the modern day 
human because it performed a role in human biology.   
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In our study of Np9 in teratocarcinoma cells, we have discovered that Np9 played 
a different role in tumorigenesis than originally expected. We initially hypothesized that 
the role of Np9 in tumorigenesis was that of promoting cell proliferation. However, the 
Np9 accessory protein actually promotes tumorigenesis by reducing the sensitivity of 
teratocarcinoma cells to environmental and chemical stresses, thus promoting cell 
viability. Further, Np9 is essential for the migration of teratocarcinoma cells, and 
migration of cancer cells is crucial for metastatic progression. Therefore, there is 
mounting evidence that the HERV-K Np9 accessory protein is an oncoprotein. Also, our 
preliminary studies on the role of Np9 in signal transduction pathways illustrate that the 
function of Np9 is complex. A continuation of the study on identifying potential 
interacting partners of Np9 could provide a clue as to the role of Np9 in 
teratocarcinoma.  
 
Conversely, preliminary studies done in collaboration with Dr. Orly Reiner and Dr. 
Tamar Sapir suggest that the expression of Np9 is beneficial for brain development 
(See Appendix). Taken together, our data suggest that the role of Np9 in human biology 
is can be either beneficial or detrimental, and will require further studies to understand 
the complexity of its role.   
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Figure 3.1 Quantitative RT-PCR of np9 mRNA in different teratocarcinoma cells. RNA was 
extracted from three teratocarcinoma cell lines: Pa-1, Tera-1, and NCCIT. qRT-PCR was performed 
to quantitate the expression of np9 mRNA in the three teratocarcinoma cells; the expression of np9 
was normalized to GAPDH, a housekeeping gene. The expression of np9 mRNA in Tera-1 and 
NCCIT was compared to that of Pa-1, as Pa-1 is a an ovarian derived teratocarcinoma cell line 
known to not produce VLPs, and is known to express little to no HERV-Ks. The expression of np9 
mRNA in the three teratocarcinoma cell lines varied, with NCCIT being the teratocarcinoma cell line 
to have the highest expression of np9. Data were obtained by Susana M. Chan. 
 
 
 
 
 
 
 
 
 
Figure 3.2 The reduced expression of Np9 in teratocarcinoma had no effect on the c-myc and 
Wnt/ß-catenin signaling pathways. Knocking down the expression of Np9 in NCCIT 
teratocarcinoma cells did not affect the Wnt/ ß-catenin signaling pathway, nor did it alter the 
expression of phosphorylated c-Myc or phosphorylated Akt. Data were obtained by Susana M. 
Chan. 
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Figure 3.3 The reduced expression of Np9 in teratocarcinoma cells downregulated the 
MAPK/Erk signaling pathway. (A) Knocking down the expression of Np9 in NCCIT cells had no 
effect on Mek1/2 and p-Mek1/2, a MAPK element upstream of Erk1/2. (B) Knocking down the 
expression of Np9 resulted in the downregulation of p-Erk1/2 and cdc25c, a downstream element of 
Erk1/2 that plays a role in cell cycle progression. The reduced expression of Np9 had no effect on 
p90RSK, a downstream element of Erk1/2 responsible for transcription. Data were obtained by 
Susana M. Chan.  
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Figure 3.4 The reduced expression of Np9 resulted in the altered regulation of Numb, a Notch 
repressive element. Knocking down the expression of Np9 in teratocarcinoma cells resulted in the 
increased phosphorylation of the Numb protein, normally a Notch repressive element. In the 
phosphorylated state, Numb is subjected to proteasomal degradation. However, there seemed to be 
no increase in Notch activation indicated by the downregulation of MAML-1, a Notch co-activator. 
Data were obtained by Susana M. Chan.   
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Appendices 
 
The role of Np9 in brain development 
 
My thesis has focused on the role of Np9 in human disease by looking at the 
function of Np9 in human teratocarcinoma cells. However, we also wondered whether, 
analogous to syncytin, Np9 might play a role in normal human development. We 
hypothesized that Np9 might be important in the development of the human brain, as 
K111 is so abundant, expressed only in human, and produces only Np9. Dr. Orly Reiner 
and Dr. Tamar Sapir at the Weizmann Institute of Science in Israel have led a 
collaboration with us on the role of Np9 in brain development and neurological diseases.  
 
Brain development throughout the course of human life is an exceptionally 
complex and time-sensitive process. During the embryonic and fetal stages of early life, 
the brain must undergo high, but modulated, levels of neuronal proliferation, 
differentiation, migration, synaptogenesis, and apoptosis. Subsequently, the brain 
continues to mature through adolescence and into adulthood in a manner and pacing 
distinct from that of its prenatal development. The precise control of these cell fate 
determinations over the course of an individual’s life is vital for the successful 
development of the human brain. Multiple signaling pathways have been identified to be 
involved in these cell fate determinations, and we and our collaborators focused on two 
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of the pathways thought to be under control of Np9: Wnt/ß-catenin and Notch (Lui, 
Hansen, and Kriegstein 2011). Alterations or imprecise control of these same pathways 
that are important for successful brain development have also been associated with 
neurological diseases such as Alzheimer’s disease and schizophrenia (Al-Harthi 2012).   
  
 During embryogenesis, Wnt expression promotes neural stem cell proliferation 
through the translocation of ß-catenin into the nucleus to act as a transcription factor 
(Lui, Hansen, and Kriegstein 2011). Later in central nervous system (CNS) 
development, Wnt signaling is important for inducing neuronal and astroglia 
differentiation and suppressing oligodendrocyte differentiation (Lui, Hansen, and 
Kriegstein 2011). The Notch signaling pathway plays a key role in the brain, activating 
the HES family genes, the BLBP gene, and both n- and c-Myc (Lui, Hansen, and 
Kriegstein 2011). As a result, during CNS development Notch signaling plays an active 
role in stem cell self-renewal, inhibiting neuronal commitment, promoting astrocyte-
oriented fates, and affecting both brain morphogenesis and neuronal migration (Lui, 
Hansen, and Kriegstein 2011). Additionally, the Notch pathway is highly active in 
ventricular radial glia cell and outer radial glia cells (Lui, Hansen, and Kriegstein 2011). 
Importantly, the results of both Wnt/ß-catenin and Notch signaling are dependent on the 
context of other signaling cascades, and thus can result in apparently opposing 
outcomes at various times in brain development.  
 
Considering the vastly increased presence of HERV-K np9 gene in humans as 
compared to primates, the complete absence in other mammals, and the interaction of 
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Np9 in pro-tumorigenic pathways that overlap with those known to be important in brain 
development, Np9 struck us as an intriguing candidate to be involved in driving the 
emergence of the modern-day human brain. We examined the expression of np9 
transcripts in post-mortem brain samples from human adults. For the study, RNA was 
extracted from five brain regions (cerebellum, amygdala, hippocampus, nucleus 
accumbens, and dorsolateral prefrontal cortex) of four deceased adult patients, and the 
expression of np9 mRNA was determined by qRT-PCR. The results of these 
experiments are shown in Figure A.1, in which the expression of np9 mRNA was 
normalized to gapdh and plotted relative to that of Tera-1 teratocarcinoma cell lines, 
previously shown to express high levels of both np9 mRNA and protein. Strikingly, all 
brain regions tested expressed equivalent or greater np9 mRNA than did Tera-1 cells.  
 
We and our collaborators hypothesized that expression of Np9 into the mouse 
embryonic brain would affect signaling in the pathways previously mentioned, and thus 
alter the developing mouse brain through changes in the number of progenitor cells and 
perhaps the ratio between different types of progenitors residing in the ventricular zone 
(VZ) and sub-ventricular zone (sVZ). Subsequently, Np9 expression might then also 
alter cell fate determination, neuronal migration, positioning in the cortex, neuronal 
morphology and/or neuronal connectivity. For our study, Np9 was expressed in the 
developing embryonic mouse brain at E13, when the relative proportion of cycling cells 
is high. Np9 was introduced by in utero electroporation of a Np9 mammalian expression 
plasmid tagged with a fluorescent protein; the fluorescent protein allowed for the 
monitoring of Np9 expression and determined the success of the electroporation. The 
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preliminary experiment was conducted in combination with a Notch reporter system, 
and showed that Np9 increased Notch activity, and altered cellular localization within 
the mouse brain after only 24 hours, with retention of cells in the apical region of the VZ 
(Figure A.2). Currently, our collaborators are knocking-down Np9 in human brain 
organoids using CRISPR/Cas9 and studying the effect on cellular migration and on the 
Wnt/ ß-catenin and Notch cell signaling pathways. Thus, while expression of Np9 can 
drive malignancy, the HERV-K protein may also play a role in healthy human brain 
development.  
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Figure A.1 Relative Np9 expression in post-mortem adult human brain samples. RNA was 
extracted from the indicated brain regions of four deceased human adults and the expression of 
HERV-K np9 mRNA analyzed compared to that of the highly expressing Tera-1 teratocarcinoma cell 
line (equal to 1) by quantitative real time RT-PCR. Amplification of gapdh mRNA was used for 
normalization, and the relative expression graphed was calculated using the ∆∆cT method. Data 
were obtained by Dr. Derek Dube.  
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Figure A.2 Forced expression of Np9 affects Notch activity in the developing cortex. CBFRE-
EGFP was in utero electroporated to E13 mouse embryos together with DsRed expression plasmid 
(A-D) or with DsRed and Np9 (E-H). The brains were collected one day later, sectioned and stained 
with anti-GFP. (I) EGFP signal represents NICD-CBF1 binding to CBF responsive element and is a 
readout for Notch activation. The Notch activity in the control brains is localized in the VZ, with a 
peak expression in the nuclei at the apical surface and a sharp drop of activity in sVZ and 
intermediate zone (IZ) (A, B J). A small portion of double labeled cells (DsRed+ EGFP+) is seen in 
the basal aspaect of the VZ and, to a lesser level, in the apical side of the VZ (D). Over-expression 
of Np9 (E-H), caused labeled cells to be retained in the apical regions of the VZ (G). These cells 
generally exhibit high Notch activity (H). A histogram (J) of signal levels along the VZ/sVZ and the IZ 
demonstrates the differences between control (orange) and Np9 over-expressing brains (blue). 
Scale is 50 microns. Data obtained by Drs. Orly Reiner and Tamar Sapir at the Weizmann Institute 
as part of an ongoing collaboration with Susana M. Chan and Dr. David Markovitz. 
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